

CURRICULUM VITAE

NAME: C. Lindsay DeVane, Pharm.D.

TITLES: Professor of Psychiatry and Behavioral Sciences
Vice Chair for Research
Director, Laboratory of Drug Disposition & Pharmacogenetics

DATE: August, 2005

OFFICE ADDRESS: Department of Psychiatry & Behavioral Sciences
Laboratory of Drug Disposition & Pharmacogenetics
Medical University of South Carolina
173 Ashley Avenue, Room CRI-408
Charleston, S.C. 29425-0742
Phone: 843-792-5448
Fax: 843-792-6318
E-mail: devanel@musc.edu

EDUCATION:

YEARS	TRAINING	LOCATION
1966 - 1971	B.S. (Pharmacy)	University of North Carolina, Chapel Hill, N.C.
1975 - 1977	Doctor of Pharmacy	Mercer University, Atlanta, GA
1977 - 1978	Residency in Clinical Pharmacy	Buffalo General Hospital, Buffalo, NY
1978 - 1980	Postdoctoral Fellowship in Pharmacokinetics	State University of New York, Department of Pharmaceutics, Buffalo, NY
1990	Professional Development Leave (Sabbatical)	National Institute of Mental Health Laboratory of Clinical Science, NIH Bethesda, MD

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 2

SPECIALTY CERTIFICATION

Board Certified Psychiatric Pharmacist (BCCP), #496296, Board of Pharmaceutical Specialties

LICENSURE

Registered Pharmacist, North Carolina (#5816) 1971 to present

FACULTY APPOINTMENTS

YEARS	RANK	DEPARTMENT	INSTITUTION
1980 - 1985	Assistant Professor	Pharmacy Practice	University of Florida,
1985 - 1990	Associate Professor	Pharmacy Practice	University of Florida
1990 - 1993	Professor	Pharmacy Practice	University of Florida
1983 - 1985	Assistant Professor	Psychiatry	University of Florida
1985 - 1990	Associate Professor	Psychiatry	University of Florida
1990 - 1993	Professor	Psychiatry	University of Florida
1994 - present	Professor (with tenure)	Psychiatry & Behavioral Sciences	Medical University of South Carolina

HOSPITAL APPOINTMENTS

YEARS	POSITION	INSTITUTION
1994 - present	Consultant Staff	MUSC Medical Center
1981 - 1993	Consultant Staff	J. Hillis Miller Health Center; VAMC, Gainesville, FL
1978 - 1980	Consultant Staff	Bry-Lin Mental Hospital, Buffalo, NY
1976 - 1977	Pulmonary Rehabilitation Team	Georgia Baptist Medical Center, Atlanta, GA
1976 - 1977	Radiopharmacist	Nuclear Pharmacy, Inc., Atlanta, GA
1975 - 1976	Pharmacist	Peachtree Mental Hospital, Atlanta, GA
1972 - 1975	Staff Pharmacist	Southeastern General Hospital

ADMINISTRATIVE APPOINTMENTS

YEARS	POSITION	INSTITUTION
2004 – present	Vice Chair for Research	Department of Psychiatry & Behavioral Sciences Medical University of South Carolina
2000 - present	Director, Laboratory of Drug Disposition &	Department of Psychiatry & Behavioral Sciences Medical University of South Carolina

Pharmacogenetics

1994 - 2000 Co-Director, Affective Department of Psychiatry & Behavioral Sciences
Disorders and Schizo- Medical University of South Carolina
phrenia Research Program

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 3

1989 - 1993 Co-Director, Anxiety Department of Psychiatry, University of Florida
Disorders Unit

1987 - 1991 Associate Chairman Department of Pharmacy Practice,
University of Florida

AWARDS, HONORS, CURRENT MEMBERSHIPS IN PROFESSIONAL SOCIETIES

American College of Neuropsychopharmacology (A.C.N.P.), Elected Member, 2002

Russell R. Miller Award, American College of Clinical Pharmacy, 2001

Judith Saklad Memorial Award, College of Psychiatric and Neurologic Pharmacists, (CPNP), 2000

Award for Achievement for Sustained Contributions to the Literature
of Pharmacy, ASHP Research and Education Foundation, 1993

Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.), Fellow, 1990

Committee membership: Credentials & Membership 2004-present

American College of Clinical Pharmacy (F.C.C.P.), Fellow, 1989

American College of Clinical Pharmacy

Board of Regents (elected 3 year term): 1992-1995

Committee membership: Annual Meeting Committee 1984-1985

Credentials Committee 1985-1987

Research Affairs Committee 1988-1989

Fellowship Committee 1992-1995; 1998-2001

Long Range Planning 1993-1994

Constitution/Bylaws 1993-1994

Executive Committee 1993-1995

Grant Review Committee 1998-2001

Executive Dir. Search Committee 2002-2003

North Carolina Pharmaceutical Association, Member 1971

American Association of Pharmaceutical Scientists, Member 2003

EDITORIAL ACTIVITIES

Editorial Board Memberships

Psychopharmacology Bulletin

Editorial Board 1991 - present

Associate Editor, Drug Interactions 2000 - present

Clinical Pharmacokinetics 2002 - present

<u>Human Psychopharmacology</u>	2002 - present
<u>Clinical Pharmacology & Therapeutics</u>	1993 - present
<u>Pharmacotherapy</u>	1993 - present
<u>Issues in Depression: Index & Reviews</u>	1998 - present
<u>Medscape [Internet] (Pharmacology)</u>	1999 - present
<u>Annals of Pharmacotherapy</u>	1984 - 1997
<u>Journal of Pharmacy Teaching</u>	1988 - 1999

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 4

Board of Directors :

<u>Pharmacotherapy</u> (3 year terms)	1996-1998; 1999-2002; 2003-2005
---------------------------------------	---------------------------------

Manuscript Referee: (reviews provided in 2000-04)

<u>Journal of Clinical Psychopharmacology</u>	<u>Clinical Pharmacokinetics</u>
<u>Journal of Chromatography</u>	<u>American Journal of Psychiatry</u>
<u>Journal of Clinical Psychiatry</u>	<u>Clinical Pharmacology & Therapeutics</u>
<u>Journal of Pharmaceutical Sciences</u>	<u>Pharmacotherapy</u>
<u>Psychopharmacology</u>	<u>Clinical Therapeutics</u>
<u>Depression & Anxiety</u>	<u>Drugs</u>
<u>Pharmacology & Toxicology</u>	<u>New England Journal of Medicine</u>
<u>J Pharmacy & Pharmacology</u>	<u>Human Psychopharmacology</u>
<u>Biological Psychiatry</u>	<u>Brit J Clin Pharmacology</u>
<u>Neuropsychopharmacology</u>	

EXTRAMURAL GRANTS

A. Federal Government--Current Funding

“PGP Regulation of Antipsychotic Exposure and Effects”, PI, National Institute of Mental Health, February 1, 2005 thru January 31, 2009, R01-MH071811, \$950,000 direct costs.

“Medications in Pregnancy: Defining Exposure”, Specialized Center of Research on Sex and Gender Factors Affecting Women’s Health (SCOR), Zachary Stowe, MD, Emory University, Atlanta, GA; CL DeVane, PI for Core A: PK/PD/PG Modeling & Data Analysis; NIMH, November 2002 thru October, 2007; \$4,348,958 direct costs; sub-contract to MUSC \$832,609.

“Bipolar Disorder in Pregnancy: Predictors of Morbidity”, D.J. Newport, PI, Emory; C.L. DeVane, PI for MUSC sub-contract, R01 MH071531, June 1, 2005 through May 31, 2010, \$2,628,562 direct costs; \$413,790 sub-contract to MUSC.

“Pharmacokinetics and Drug Interactions of Milk Thistle”, Co-Investigator (J.S. Markowitz, PI),

National Center for Complimentary and Alternative Medicine, April 1, 2005 thru March 31, 2008; \$375,000 direct costs.

“Drug Interactions and Bioavailability of Cranberry”, Co-Investigator (J.S. Donovan, PI) NCCAM, 12/01/2003 thru 11/30/2006, \$275,000 direct costs; 10% effort.

“CBT and Modafinil for Cocaine Addiction”, Co-Investigator (R.M. Malcolm, PI) NIDA, 12/1/03 thru 11/20/07, \$1,200,348 direct costs.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 5

Past Federal Funding

“Pharmacogenetics of Methadone in Pregnancy”, Principal Investigator, National Institute of Drug Abuse, April 1, 2001 thru March 31, 2005 , R01-DA13027, \$750,000 direct costs.

“Ethylphenidate Formation from Alcohol and Methylphenidate”, Co-Investigator (K.S. Patrick, PI) National Institute of General Medical Sciences, April 1, 2003 to March 31, 2005.

“Screening Herbal Agents for Metabolic Drug Interactions”, Co-Investigator (J.S. Markowitz, PI), National Center for Complimentary and Alternative Medicine (NIH-NCCAM), April 1, 2001 thru March 31, 2004, \$250,000 direct costs; 10% effort.

“Clinical Trials Operations”, Medications Development Program, National Institute of Drug Abuse, Principal Investigator for Contract Phase I studies, 2000 thru 2005, ~\$400,000/study/yr; Current project: “Drug Interactions of Cocaine and Modafinil”, Sept 2000 thru November, 2002. \$550,535 direct costs; 33% effort.

"Disposition and Pharmacodynamics of Cocaine in Pregnancy," Principal Investigator, National Institute of Drug Abuse, 1987 thru 1991, R01-DA05190, \$335,323.

"Dosage Regimen Design for Drugs with Active Metabolites," Principal Investigator, NIMH, July 1, 1981 thru June 30, 1982, R03-MH36369, \$6,250.

"Placental Transfer of Lipid Soluble Drugs," Co-Principal Investigator, National Institute of Child Health and Human Development, April 1, 1982 thru March 30, 1985, R01-HD14075, \$335,891; competitive renewal funded 1985-1988, \$300,000.

"Physiological Model for Placental Transfer of Xenobiotics," Principal Investigator, Environmental Protection Agency, 1986-1987, \$5,000.

"SPECT Imaging of Neuroreceptors," Co-Investigator, Veterans Administration, 1990-1993, \$77,000/yr.

"Effects of Cocaine on Placental Growth Factors", NIDA, R01-DA06890, Co-Investigator, 10%, 1991-1993, \$296,250.

B. Foundation

"Pharmacokinetics for Psychiatrists--Evaluation of a Training Program in Therapeutic Drug Monitoring," Principal Investigator, National Fund for Medical Education, July 1983 thru July 1985, \$62,603.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 6

C. Industry (Previous Five Years) (*Funding Disclosure Non-Public*)

Only Investigator-Initiated Studies with C.L. DeVane as PI or Co-PI are Listed; Participation on Numerous Multi-Center Clinical Trials as Co-Investigator are Unlisted

“Risperidone and Drug Transporter Interactions, Janssen Pharma, Inc. 2004-2005

“Olanzapine and Oral Absorption”, Eli Lilly, Inc., 2004

“Olanzapine Plasma Concentrations and Clinical Effects”, Eli Lilly, Inc., 1998-2001.

“Drug Interaction Potential on Cytochrome 3A4 of Four Antidepressants”, Wyeth-Ayerst, Inc., Principal Investigator, 1999-2000.

“Time Course of Enzyme Inhibition of Newer Antidepressants”, SmithKline Beechem; “Drug Interaction Potential on Cytochrome 3A4 of Four Antidepressants”, Wyeth-Ayerst, Inc., Principal Investigator, 1999-2000.

“Time Course of Enzyme Inhibition of Newer Antidepressants”, SmithKline Beechem; Principal Investigator, 1999-2000.

“Interaction of Atypical Antipsychotics with Glucuronyltransferases”, Janssen Research Foundation, Co-Principal Investigator, 1999-2000.

“Atypical Antipsychotic Affinity for P-glycoprotein”, Astra Zeneca, 2000-2001. Principal Investigator

D. Intramural Funding

"SPECT Imaging of Alpha-1 Receptors in Depression," Principal Investigator, University of

Florida Development Competition Award, 1989-1990, \$18,877.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 7

"Psychoactivity of Bupropion's Metabolite," Principal Investigator, University of Florida Division of Sponsored Research, Faculty Research Development Award, 1985-1986, \$20,597.

"HPLC Development for Second Generation Antidepressants," Principal Investigator, University of Florida Division of Sponsored Research, New Faculty Development Award Program, 1981, \$5,700.

"Development of a Method to Determine CSF Drug Delivery," Principal Investigator, College of Pharmacy BSRG Program, 1982, \$3,000.

"Chronopharmacology of Drug Binding Proteins," Principal Investigator, College of Pharmacy BSRG Program, 1983, \$5,000.

E. Other Sources of Support

"Fellowship in Psychiatric Pharmacotherapy," Preceptor, American Society of Hospital Pharmacists, 1986, \$19,500.

"Development of a Pharmacy Residency in Psychiatry," Preceptor, Veterans Administration Medical Center Gainesville, FL, \$22,500/yr; 1983 to 1993.

Clinical Pharmacy Research Fellowship, Research Institute of the American College of Clinical Pharmacy, Fellowship Preceptor for Harry S. Gill, Pharm.D., 1996-1997, \$24,000

Clinical Pharmacy Research Fellowship, Research Institute of the American College of Clinical Pharmacy, Fellowship Preceptor for Heidi Liston, Pharm.D., 2000-2001, \$24,000

ACADEMIC COMMITTEE ACTIVITIES (MUSC)

University Research Council, 2005-2007

Search Committee, Associate Provost for Research, 2005

Management Committee, Department of Psychiatry, MUSC 2004 to present

Finance Committee, Department of Psychiatry, MUSC 2004 to present

Task Force for Development of Strategic Plan for Research, Chair, 2005

General Clinical Research Center (GCRC) Scientific Advisory Committee MUSC 2000-2002

Outside Activities Review Committee, Department of Psychiatry, MUSC, 2000-present

Dean's Committee for Research Scholarship, College of Pharmacy, MUSC, 1998-1999

Institute of Psychiatry Research Coordination Committee, 1994 - 1997.

Department of Health & Human Services (Columbia, SC) Ad Hoc Committee for Drug Utilization Review (1995 - 1996).

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 8

Previous Committee Appointments (University of Florida)

Faculty Appointments Committee, 1981
Sunland Center Pharmacy Search Committee, 1981
Committee on Fellowship Policies, 1982
Committee on Computer Utilization, 1982
Department of Psychiatry Committee on Case Reviews for HRS, 1985
Oncology Search Committee (Chairman), 1986
Promotion in Rank Committee, 1987
Research Planning Task Force, 1991-1992
Graduate Studies Committee, 1983-present
Faculty Retreat Committee (Chairman), 1984
College Instrumentation Committee, 1984-1992
GRECC Pharmacology Conference Planning Committee, 1984
Faculty Administrative Review Committee, 1984
K.F. Finger Award Committee, 1984
Pharmaceutics Department Chairman Search Committee, 1985
College Committee on Computing (Chairman), 1987
Representative for Orphan Drug Consortium, 1987
LRC Committee, 1988
Mission Statement Task Force, 1990
Clerkship Site Selection, 1988-1992
Tenure and Promotion Committee, 1991-1993

MAJOR TEACHING RESPONSIBILITIES (CURRENT)

Provide seminars to psychiatric PGY2-4 residents, and Doctor of Pharmacy students on drug metabolism and disposition, pharmacokinetics/dynamics, drug-drug interactions, and various topics involving pharmacotherapy of mental illness.

MAJOR RESEARCH INTERESTS

Assessment of mechanisms and effects of drug-drug interactions of psychoactive drugs; pharmacokinetics and pharmacodynamics of psychoactive drugs; mechanisms and treatment of anxiety, mood, and psychotic disorders; placental transfer of lipid soluble drugs; the effects of age and disease states on drug and metabolite disposition.

EXTRAMURAL PROFESSIONAL ACTIVITIES

Patent

U.S. Patent No. 5,525,347 issued June 11, 1996 (with C.H. Kellner & C.W. Jackson): "Composition and Methods for Treating Performance Anxiety"

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 9

University/National Committees/Professional Distinctions

NIH Pharmacology Study Section (Ad Hoc) for Pharmacogenetic Consortium Grants, 2001

Ad Hoc Committee for Meconium Screening Contracts, NIDA-NICHD, 1992-1993.

Member, Human Development Research Special Review Committee, National Institute of Drug Abuse, 1990-91.

Member, Clinical Research Center (CRC) Advisory Committee, J. Hillis Miller Health Center, University of Florida, 1988-1993.

Member, Institutional Review Board, J. Hillis Miller Health Center, University of Florida, 1987 - 1989.

Member, Formulary Committee, Health and Rehabilitative Services, State of Florida, Sept. 1986-Jan. 1990; Vice-Chairman, 1989-1991.

Member, Division of Sponsored Research Faculty Grant Review Committee, University of Florida, 1985-1988.

Member, Planning Committee, NIDA-AACP-AACP Clinical Pharmacy Research Development Project, 1991-1992.

Faculty Advisor, Pi Kappa Phi Fraternity, University of Florida, Sept. 1980-Sept. 1982.

Faculty Senate, University of Florida, 1991-1993.

Consultant, State of Florida HRS Clozapine Project, 1990-1991.

Astra Clinical Pharmacy Research Award Selection Committee, 1992-1994; 1997-1998

Postdoctoral Residents/Fellows Supervised

<u>Year</u>	<u>Student</u>	<u>Present Position</u>
1983-1984	Lois J. Birkhimer, Pharm.D.	Independent Consultant Atlanta, GA
1983-1985	S. Casey Laizure, Pharm.D.	Associate Professor, University of Tennessee
1984-1986	Cynthia S. Dommissie, Pharm.D.	Regulatory Affairs Zeneca Inc. Wilmington, DE
1985-1986	Lisa Miller, Pharm.D.	Pharmacy Services Washington Hospital Little Rock, AK
1986-1987	Carolyn Lim, Pharm.D.	E.R. Squibb and Sons Princeton, NJ
1987-1988	Lonald Daughtry, Pharm.D.	Associate Professor, Howard University Washington, DC

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 10

1987-1989	Steve Braun, Pharm.D.	Grant Center Hospital Miami, FL
1988-1990	Rick Jarecke, Pharm.D.	CNS Division, Janssen, Princeton, NJ
1988-1989	Lelia Brigmon, Pharm.D.	VA Medical Center Athens, Georgia
1989-1990	Melanie Hanna, Pharm.D.	Pharmacy Practice, Univ Florida
1990-1992	Gary Levin, Pharm.D.	Professor & Chair, Nova Southeastern College of Pharmacy Ft. Lauderdale, FL
1991-1992	Jose Rey, Pharm.D.	Associate Professor Southeastern College of Pharmacy-Miami, FL
1992-1993	George Foose, Pharm.D.	Com-Care, Inc. Phoenix, Arizona
1993-1994	Chuck Provanzano, Pharm.D.	Pharmacy Practice University of Florida
1993-1994	Matthew Byerly, M.D.	Department of Psychiatry, University of Texas
1995-1997	Harry Gill, Pharm.D.	(Deceased)
1998-1999	Seetal Dodd, Ph.D.	Department of Psychiatry, University of Melbourne, Melbourne, Australia
1998-2001	David Boulton, Ph.D.	Clinical Discovery Section Bristol Myers Squibb, Princeton, NJ
1999-2001	Heidi Liston, Pharm.D.	Professional Affairs Bristol Myers Squibb, Princeton, NJ
2001-2003	Jennifer Donovan, Ph.D.	Research Assistant Professor Department of Psychiatry, MUSC
2002-present	Jun-Sheng Wang, M.D., Ph.D.	Department of Psychiatry Medical University of South Carolina
2004-present	Hoejie Zhu, Ph.D.	Department of Psychiatry Medical University of South Carolina

SCIENTIFIC BIBLIOGRAPHY

Books, Chapters and Other Monographs, Journals, Letters

1. DeVane CL: Burned-Out Pharm.D.'s. **Drug Intell Clin Pharm** 1978;12:427.
2. DeVane CL, Wolin RE, and Jusko WJ: Pharmacokinetic Basis for Predicting Steady-State Serum Drug Concentrations of Imipramine From Single Dose Data. **Commun Psychopharmacol** 1979;3:353-357.
3. DeVane CL: "Tricyclic Antidepressants," In: Evans WE, Schentag JJ, and Jusko WJ (eds.): **Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring**, Applied Therapeutics Inc., San Francisco, 1980;549-585.
4. DeVane CL: Temazepam Evaluation. **Pharmacotherapy** 1981;1:12.
5. DeVane CL and Jusko WJ: "Pharmacokinetics of High Clearance Drugs and Their Metabolites," In: Usdin E, Dahl S, Gram LF, and Lingjaerde O (eds.): **Clinical Pharmacology in Psychiatry**, MacMillan Press, London, 1981; 253-262.
6. DeVane CL, Savett M, and Jusko WJ: Desipramine and 2-Hydroxy Desipramine Pharmacokinetics in Normal Volunteers. **Eur J Clin Pharmacol** 1981;19:61-64.
7. DeVane CL, Wolin RE, Rovere RA, Panahon NC, Sutfin TA, and Jusko WJ: Excessive Plasma Concentrations of Tricyclic Antidepressants Resulting From Usual Doses. **J Clin Psychiatry** 1981;42:143-147.
8. DeVane CL and Jusko WJ: Plasma Concentration Monitoring of Hydroxylated Metabolites of Imipramine and Desipramine. **Drug Intell Clin Pharm** 1981;15:263-266.
9. DeVane CL and Jusko WJ: "The Effect of Combining Serum Drug and Metabolite Concentrations on the First Day Test Dose Versus Steady-State Relationship for Predicting Maintenance Drug Dose," In: **Proceedings of the First European Congress of Biopharmaceutics and Pharmacokinetics**, Technique et Documentation, Paris, 1981;58-67.
10. DeVane CL: Clinical Pharmacokinetics of Benzodiazepines by V. Klotz, L. Kangas, and J Kanto, Fischer Verlag, New York, 1980 (book review). **Drug Intell Clin Pharm** 1982;16:68.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 12

11. Moskovitz R, DeVane CL, Harris R, and Stewart RB: Imipramine Associated Hepatitis with Normal Drug Concentrations. **J Clin Psychiatry** 1982;43:165-166.
12. DeVane CL and Ahsanuddin K: Dosage Regimen Design for Pediatric Psychiatry. **Islamic Med J** 1982;14:149-150.
13. Pentel PR, Bullock ML, and DeVane CL: Hemoperfusion for Imipramine Overdose: Elimination of Active Metabolites. **J Toxicol: Clin Toxicol** 1982;19:239-248.
14. DeVane CL and Jusko WJ: Dosage Regimen Design. **Pharmacol Ther** 1982;17:143-163.
15. DeVane CL and Hodgins J: Triazolam Evaluation. **Pharmacotherapy** 1983;3:146-147.
16. DeVane CL: Pharmacokinetics, 2nd edition by M. Gibaldi and D. Perrier, Marcel Dekker, New York, 1982 (book review) **Biopharm Drug Disp** 1983;4:201.
17. Carson S and DeVane CL: The Estimation of Half-Life with a Pocket Nomogram for Use in Therapeutic Drug Monitoring, **Am J Hosp Pharm** 1983;40:1696-1698.
18. Ahsanuddin K and DeVane CL: Enuresis. **Islamic Med J** 1983;15:30-32.
19. DeVane CL, Director K, and Adams J: "Drug Interactions Involving Anti-anxiety Agents and Hypnotics," In: Petrie JD and Cluff LE (eds.): **Clinically Important Adverse Drug Interactions**, Elsevier/North Holland, 1984;29-45.
20. DeVane CL: Clinical Application of Antipsychotic Plasma Concentrations. **ASHP SIGNAL** 1984;8(2):11-12.
21. DeVane CL and Jusko WJ: Drug and Metabolite Concentrations Combined in Predicting Steady-State Concentrations From Test Doses. **Biopharm Drug Disp** 1983;4:19-29.
22. DeVane CL, Walker RD, Sawyer WP, and Wilson JA: Concentrations of Imipramine and Its Metabolites During Enuresis Therapy. **Pediatr Pharmacol** 1984;4:245-251.
23. Sutfin TA, DeVane CL, and Jusko WJ: The Analysis and Disposition of

Imipramine and Its Active Metabolites, Psychopharmacology 1984;82:310-317.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 13

24. Stout SA and DeVane CL: Quantification of Imipramine and Its Major Metabolites in Whole Blood, Brain, and Other Tissues by Liquid Chromatography, Psychopharmacology 1984;84:39-41.
25. DeVane CL, Stout SA, and Simpkins JM: Cerebral and Blood Pharmacokinetics of Imipramine in the Pregnant Rat, Psychopharmacology, 1984;84:225-230.
26. Birkhimer LB, DeVane CL, and Muniz CE: Interactions Involving Psychotherapeutic Drugs: Mechanisms and Management, South Med J 77:465-469, 1984.
27. DeVane CL: Dependence on Tranquilizers, by H. Peterson and M. Lader, Oxford Press, New York, 1984 (book review). Drug Intell Clin Pharm 1985;19:322.
28. Stout SA and DeVane CL: Tissue Assay for Phenobarbital, Phenytoin, and Parahydroxyphenytoin by High Pressure Liquid Chromatography. J Chromatogr 1984;285:500-508.
29. DeVane CL, Wailand LA, and Jusko WJ: Stability of Chlorpromazine in Five Milliliter Vials. Can J Hosp Pharm 1984;37:9.
30. DeVane CL and Ahsanuddin K: Imipramine Prescriptions for Children. Drug Intell Clin Pharm 1983;17:562-564.
31. DeVane CL and Stewart RB: Differences in Diazepam and Oxazepam. Arch Gen Psychiatry 1984;41:311.
32. Birkhimer LJ and DeVane CL: The Neuroleptic Malignant Syndrome: Presentation and Treatment. Drug Intell Clin Pharm 1984;18:462-465.
33. DeVane CL and Simpkins JW: Pharmacokinetics of Imipramine and Its Major Metabolites in Pregnant Rats and Their Fetuses Treated with a Single Dose. Drug Metab Disp 1985;13:438-442.
34. Birkhimer LJ, DeVane CL, and Muniz CE: Post Traumatic Stress Disorder: Characteristics and Pharmacological Response in the Veteran Population.

Compr Psychiatry 1985;26:304-310.

35. Yost RL and DeVane CL: Diurnal Variation of Alpha-1-Acid Glycoprotein Concentrations in Normal Volunteers. **J Pharm Sci** 1985;74:777-779.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 14

36. Curry SH, DeVane CL, and Wolfe MM: Cimetidine Interactions with Amitriptyline. **Eur J Clin Pharmacol** 1985;29:429-433.
37. Dommissie CS and DeVane CL: Buspirone: A New Type of Anxiolytic. **Drug Intell Clin Pharm** 1985;19:624-628.
38. Laizure SC, DeVane CL, Stewart JT, Dommissie CS, and Lai AA: Pharmacokinetics of Bupropion and Its Major Basic Metabolites in Normal Volunteers. **Clin Pharmacol Ther** 1985;38:586-589.
39. Laizure SC and DeVane CL: The Stability of Bupropion and Its Major Metabolites in Human Plasma Under Varying Storage Conditions. **Ther Drug Monit** 1985;7:447-450.
40. Miller RL and DeVane CL: Analysis of Trazodone and M-Chloro-Phenylpiperazine in Plasma and Brain Tissue by High Performance Liquid Chromatography. **J Chromatogr** 1985;374:388-393.
41. Dommissie CS, DeVane CL, and Hayes PE: Cortisol Suppression Index. **J Clin Psychiatry** 1985;46:505.
42. Miller RL and DeVane CL: Measurement of Haloperidol and Reduced Haloperidol in Human Plasma Using Reversed-Phase High-Performance Liquid Chromatography. **J Chromatogr** 1985;374:405-408.
43. DeVane CL and Jusko WJ: "Dosage Regimen Design," In: M. Rowland and G. Tucker (eds.): **Pharmacokinetics: Theory and Methodology, International Encyclopedia of Pharmacology and Therapeutics**, Pergamon Press, London, 1986;213-236.
44. Curry SH, Laizure C, and DeVane CL: Spread-Sheet Analysis in Pharmacokinetic Simulations. **Trends Pharmacol Sci** 1986;7:220-223.
45. DeVane CL: "Cyclic Antidepressants," In: Evans WE, Schentag JJ, and Jusko WJ (eds.): **Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring**, 2nd edition, Applied Therapeutics

Inc., San Francisco, 1986; 852-909.

46. DeVane CL and Laizure SC: The Effect of Experimentally Induced Renal Failure on Accumulation of Bupropion and Its Major Basic Metabolites in Plasma and Brain of Guinea Pigs. **Psychopharmacology** 1986;89:404-408.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 15

47. DeVane CL and Simpkins JW: "Placental Transfer and Teratogenic Effects of Imipramine in the Rat," In: Paul SM, Gram LF, Dahl S, and Potter WZ (eds): **Clinical Pharmacology in Psychiatry: IV. Selectivity in Drug Action**, Springer Verlag, 1986;171-175.
48. Curry SH, DeVane CL, and Wolfe MM: Pharmacology of Combined Antidepressant/H₂-Blocking Drug Therapy. **Psychopharmacol Bull** 1986;220-222.
49. Fuller AK, Tingle D, DeVane CL, Scott JA, Stewart RS: Haloperidol Absorption and Clinical Efficacy Following Gastric Bypass Surgery for Obesity. **J Clin Psychopharmacol** 1986;6:376-377.
50. DeVane CL: "Laboratory Analysis of Biological Samples: Avoiding the Pitfalls with Cyclic Antidepressants," In: E. Reid (ed): **Methodologic Surveys in Biochemistry and Analysis**, Plenum Press, New York, 1986;149-157.
51. Curry SH, DeVane CL, and Wolfe MM: Lack of Interaction of Ranitidine with Amitriptyline. **Eur J Clin Pharmacol** 1987;32:317-320.
52. DeVane CL: Naming the Cyclic Antidepressants. **J Clin Psychopharmacol** 1987;7:285-286.
53. DeVane CL and Tingle D: "Psychiatric Disorders in the Elderly," In: Delafuente JC and Stewart RB (eds): **Therapeutics for the Elderly**, Williams and Wilkins, New York, 1987;185-195.
54. DeVane CL: "Monitoring Cyclic Antidepressants," In: Therapeutic Drug Monitoring, B. Gerson (ed): **Clinics in Laboratory Medicine**, W.B. Saunders, Philadelphia, 1987;7:551-566.
55. Curry SH, DeVane CL, and Wolfe MM: Hypotension and Bradycardia Induced by Amitriptyline in Healthy Volunteers **Hum Psychopharmacol** 1988;3:47-52.
56. Golden RN, DeVane CL, Laizure SC, Rudorfer MV, Sherer MA, Potter WZ: Bupropion: The Role of Metabolites in Clinical Outcome. **Arch Gen Psychiatry** 1988;45:145-149.

57. Miller RL and DeVane CL: Alprazolam, Alpha-Hydroxy and 4-Hydroxyalprazolam Analysis in Plasma by High Performance Liquid Chromatography. **J Chromatogr** 1988;430:180-186.
58. Aulakh CS, Wozniak KM, Hill JL, DeVane CL, Tolliver TJ, and Murphy DL: Differential Neuroendocrine Responses to the 5-HT Agonist m-Chlorphenylpiperazine in Fawn-Hooded Rats Relative to Wistar and Sprague-Dawley Rats. **Neuroendocrinology** 1988;48:401-406.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 16

59. Lim CL and DeVane CL: Retroperitoneal Fibrosis. **Drug Intell Clin Pharm** 1988;22:6.
60. DeVane CL, Simpkins JW, Miller RL, and Braun SB: Tissue Distribution of Cocaine in the Pregnant Rat. **Life Sci** 1989;45:1271-1276.
61. DeVane CL: Quazepam Evaluation. **Pharmacotherapy** 1990;10:12.
62. DeVane CL: "Pharmacokinetic Correlates of Fetal Drug Exposure", In: Chiang N (ed), **Methodological Issues in Controlled Studies on the Effects of Prenatal Drugs**, National Institute of Drug Abuse, Washington, D.C., Research Monograph 1991;114:18-36.
63. Meyer EM, Potter LT, DeVane CL, Irwin I, and Rutenber AJ: Effects of Benzoyltropine and Tropacocaine on Several Cholinergic Processes in the Rat Cerebral Cortex. **J Pharm Exp Ther** 1990;254:584-590.
64. Ware MR, Frost ML, Berger JJ, Stewart RB, and DeVane CL: Electroconvulsive Therapy Complicated by Insecticide Ingestion. **J Clin Psychopharmacol** 1990;10:72-73.
65. DeVane CL, Laizure SG, Stewart JT, Kolts BE, and Lai AA: Disposition of Bupropion in Healthy Volunteers and Subjects with Alcoholic Liver Disease. **J Clin Psychopharmacol** 1990;10:328-332.
66. Ware MR, and DeVane CL: Successful Treatment of Panic Disorder During Pregnancy With Imipramine **J Clin Psychiatry** 1990;51:482-484.
67. DeVane CL: **Fundamentals of Monitoring Psychoactive Drug Therapy**, Williams & Wilkins, Inc., Baltimore, 1990; 1-287. [sole-authored textbook]
68. DeVane CL and Jarecke R: "Cyclic Antidepressants", In: Evans WE, Schentag JJ, and Jusko WJ (eds): **Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring**, 3rd edition, Applied Therapeutics, San Francisco, 1992;3301-3347.

69. DeVane CL, Simpkins JW, and Stout SA: Distribution of Phenobarbital and Phenytoin in Pregnant Rats. **Epilepsia** 1991;32:250-256.
70. DeVane CL, Lim C, Carson S, Tingle D, Hackett L, and Ware MR: Effect of Electroconvulsive Therapy on Serum Concentration of Alpha-1-Acid Glycoprotein and Cortisol. **Biol Psychiatry** 1991;30:116-120.
71. Osman OT, DeVane CL, Greenblatt DJ, and Potter WZ: Pharmacokinetic and Dynamic Correlates of Intravenous Alprazolam Challenge. **Clin Pharmacol Ther** 1991;50:656-662.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 17

72. Ware MR and DeVane CL: Treatment of Panic Disorder During Pregnancy. **Human Aspects Med Sexuality** 1991;25(3):45.
73. Delafuente JC and DeVane CL: Immunologic effects of cocaine and related alkaloids. **J Immunol Toxicol** 1991;13:11-23.
74. DeVane CL, Burchfield DJ, Abrams RM, Miller RL, and Braun SB: Disposition of Cocaine in Pregnant Sheep, Part I. Pharmacokinetics. **Dev Pharmacol Ther** 1991;16:123-129.
75. Burchfield DJ, Abrams RM, Miller RL, and DeVane CL: Disposition of Cocaine in Pregnant Sheep: Part II. Pharmacodynamics. **Dev Pharmacol Ther** 1991;16:130-138.
76. DeVane CL: Pharmacokinetics of the Selective Serotonin Re-Uptake Inhibitors. **J Clin Psychiatry** 1992;53(2S):13-20.
77. Ware MR, Marchese MJ, DeVane CL, and Hall KL: Major Depression: Assessment and Initial Pharmacotherapy for the Family Physician **Family Practice Recertification** 1991;13:69-85.
78. Burchfield DJ, Lucas VW, Abrams RM, Miller RL, and DeVane CL: Disposition and Pharmacodynamics of Methamphetamine in Pregnant Sheep **JAMA** 1991;265:1969-1975.
79. Burchfield DJ, Abrams RM, Miller RL, and DeVane CL: Inhalational Administration of Cocaine in Sheep **Life Sci** 1991;48:2129-2136.
80. Miller RL and DeVane CL: Determination of Cocaine, Benzoylcegonine and Ecgonine Methyl Ester by Reversed Phase HPLC **J Chromatogr** 1991;570:412-418.
81. DeVane CL, Ware MR, and Lydiard B: Pharmacokinetics, Dynamic and Treatment Issues of Benzodiazepines: Alprazolam, Adinazolam, and Clonazepam.

Psychopharmacol Bull 1992;27:463-473.

82. DeVane CL, Rudorfer MV, and Potter WZ: Dosage Regimen Design for Cyclic Antidepressants: A Review of Pharmacokinetic Methods. **Psychopharmacol Bull** 1992;27:619-631.
83. Kirkwood CK, Moore A, Hayes PE, DeVane CL, and Pelonero AL: Influence of Menstrual Cycle and Gender on Alprazolam Pharmacokinetics **Clin Pharmacol Ther** 1991;50:404-409.
84. Pato M, Murphy DL and DeVane CL: Sustained Plasma Concentrations of Fluoxetine and/or Norfluoxetine Four and Eight Weeks After Fluoxetine Discontinuation **J Clin Psychopharmacol** 1991;11:224-225.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 18

85. Levin GM and DeVane CL: Case and Comment: Serotonin Syndrome. **Patient Care** 1992;26:329-330.
86. DeVane CL: "Pharmacotherapy of Anxiety Disorders", In: **Pharmacotherapy Self Assessment Program**, T.R. Host, et al (eds), American College of Clinical Pharmacy, Kansas City, MO, 1992;151-162.
87. DeVane CL: "Cyclic Antidepressants", In: **Handbook of Pharmacokinetic and Pharmacodynamic Data**, Murphy, J. (ed), American Society of Hospital Pharmacists, Bethesda, MD, 1993; 49-70.
88. Levin GM and DeVane CL: A Review of Cyclic Antidepressant Induced Blood Dyscrasias **Ann Pharmacotherapy** 1992;26:378-383.
89. Ware, MR, DeVane CL, and Hall K: Panic Disorder in Primary Care - Diagnosis and Management. **Post Graduate Medicine** 1992;91:99-108.
90. Khob V, DeVane CL, and Kirch D: The Assessment and Clinical Implications of Haloperidol Acute Dose, Steady State, and Withdrawal Pharmacokinetics **J Clin Psychopharmacol** 1993;13:120-127.
91. DeVane CL: "Pharmacokinetics and Pharmacodynamics, Volume 3. Peptides, Peptoids, and Proteins," ed. by P.D. Garzone, W.A. Colburn, and M. Mokotoff (book review) **Clin Pharm** 1992;11:277-278.
92. DeVane CL: "Research Proposals: A Guide to Success," by T.E. Ogden (book review) **Ann Pharmacotherapy** 1992;26:567.
93. Kempf JP, DeVane CL, Levin GM, Jarecke R, and Miller RL: Treatment of Aggressive Children with

Clonidine: Results of An Open Pilot Study **J Am Acad Child Adoles Psych** 1993;32:577-581.

94. DeVane CL, Grasela TH, Antal EJ, and Miller LF: Application of Population Pharmacokinetics in Therapeutic Trials. IV. Application to Postmarketing Surveillance. **Clin Pharmacol Ther** 1993;53:521-528.
95. Tueth M, DeVane CL, and Evans DL: "Treatment of Psychiatric Emergencies," In: AF Schatzberg, CB Nemeroff (eds) **Textbook of Psychopharmacology**, APA Press, 1995;769-781.
96. Levin, GM and DeVane CL: Prescribing Attitudes of Different Physician Groups Regarding Fluoxetine. **Ann Pharmacotherapy** 1993;27:1443-1447.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 19

97. DeVane CL: Brief Comparison of the Pharmacokinetics and Pharmacodynamics of the Standard and Newer Antipsychotic Drugs. **Am J Hosp Pharm** 1995;52(suppl 1):15-18.
98. DeVane CL: "Pharmacokinetic and Pharmacodynamic Approaches for the Design and Screening of Potential Medications for the Pregnant Addict", In: Chaing N. and Finnegan LP (Eds.) **National Institute of Drug Abuse**, Washington, D.C., **Research Monograph 149**, 1995;116-129.
99. Salhab AS, DeVane CL, Medrano T, Buhi WC and Shiverick KT: The Transplacental Effects of Cocaine on Growth Factors in Pregnant Rats. **J Pharm Exp Ther** 1994; 270:392-398.
100. Nadeau SE, Couch MW, DeVane CL, Shukla SS, and Williams CM: A Regional Analysis of D2-Dopamine Receptors in Parkinson's Disease Using [¹²³I]-Iodobenzamine SPECT. **J Nuclear Med** 1995;36:384-393.
101. DeVane CL: Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents. **J Clin Psychiatry** 1994;55(12,suppl):38-45.
102. DeVane CL: Pharmacokinetics of the Newer Antidepressants: Clinical Relevance. **Am J Med** 1994;97(Suppl 6A):13-23.
103. Sweet RA, Pollock BG, Perel JM, Wright B, Kirshner M, Altieri LP, and DeVane CL: Bupropion Pharmacokinetics in the Elderly. **J Clin Pharmacol** 1995;35:876-884.
104. Tyson SC, DeVane CL, and Risch CR: Probable Pharmacokinetic Interaction between Risperidone and Clozapine **Am J Psychiatry** 1995;152:1401-1402.
105. DeVane CL: Nefazodone--A Serotonin Receptor Modulator with Antidepressant Efficacy.

P & T 1995;20:363-374.

106. DeVane CL and Sallee FR: Selective Serotonin Reuptake Inhibitors in Child and Adolescent Psychopharmacology: A Review of Published Experience. **J Clin Psychiatry** 1996;57:55-63.
107. DeVane CL: Comparative Safety and Tolerability of Selective Serotonin Reuptake Inhibitors. **Human Psychopharmacol** 1995;10:S185-S193.
108. Byerly MJ and DeVane CL: Pharmacokinetics of Clozapine and Risperidone: A Review of Recent Literature. **J Clin Psychopharmacol** 1996;16:177-187.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 20

109. Sallee FR and DeVane CL: "Attention-Deficit/Heperactivity Disorder. **A Continuing Education Monograph for Pharmacists**." Medicine-In-Print, Inc., Morristown, NY, 1995;1-28.
110. Nemeroff CB, DeVane CL, and Pollock BG: Antidepressants and the Cytochrome P450 System. **Am J Psychiatry** 1996;153:311-320.
111. Borison RL, Romano S, Daniel DG, Davidson J, DeVane CL, Hansen MS, Horne R, Lieberman JA, Miller D, Remington G: Changing Antipsychotic Medication: Guidelines on the Transition to Treatment with Risperidone. **Clin Therapeutics** 1996;18:592-607.
112. DeVane CL: Pharmacogenetics and Drug Metabolism (letter) **J Clin Psychiatry** 1996;57:225-227.
113. DeVane CL: Pharmacokinetics of the Newer Antidepressants (letter) **Am J Medicine** 1996;100:120-121.
114. DeVane CL: Drug Interactions and Antipsychotic Therapy **Pharmacotherapy** 1996;16:(Part2):15-20.
115. Nemeroff CB, DeVane CL, and Pollock BG: Summary and Review of Antidepressants and the Cytochrome P450 System. **Progress Notes** 1996;6:38-40.
116. Cohen LJ and DeVane CL: Clinical Implications of Antidepressant Pharmacokinetics and Pharmacogenetics. **Annals Pharmacotherapy** 1996;30:1471-1480.

117. DeVane CL: Panic Disorder: Recent Advances in Pharmacotherapy with Selective Serotonin Re-Uptake Inhibitors. **Pharmacotherapy** 1997;17:282-292.
118. Tueth MJ, DeVane CL, and Evans DL: "Treatment of Psychiatric Emergencies", In: AF Schatzberg & CB Nemeroff (Eds) **American Psychiatric Press Textbook of Psychopharmacology**, 2nd edition, 1998; 917-929.
119. DeVane CL: "Principles of Pharmacokinetics and Pharmacodynamics", In: AF Schatzberg & CB Nemeroff (Eds) **American Psychiatric Press Textbook of Psychopharmacology**, 2nd edition 1998; 155-169.
120. McKinney PA, Finkenbine RD, and DeVane CL: Alopecia and Mood Stabilizer Therapy. **Ann Clin Psychiatry** 1996;8:183-185.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 21

121. DeVane CL and Gill HS: Clinical Pharmacokinetics of Fluvoxamine: Applications to Dosage Regimen Design. **J Clin Psychiatry** 1997;58(Suppl 5):7-14.
122. Edge S, Markowitz J, and DeVane CL: Clozapine Drug-Drug Interactions: A Review of the Literature. **Human Psychopharmacol** 1997;12:5-20.
123. Markowitz J and DeVane CL: The Drug Interaction Potential of Fluoxetine, Sertraline, and Paroxetine in Four State Psychiatric Hospitals. **Ther Drug Monitor** 1997;19:244-245.
124. Ware MR, Caton D, and DeVane CL: The Practical Use of Carbon Dioxide-Induced Anxiety in the Diagnosis and Care of Patients with Panic Disorder. **Ann Clin Psychiatry** 1996;8:199-202.
125. Markowitz JS, Gill HS, Lavia M, Brewerton TD, and DeVane CL: Fluvoxamine-Clozapine Dose Dependent Interaction. **Can J Psychiatry** 1996;41:670-671.
126. DeVane CL, Gill HS, Markowitz JS, and Carson WH. Awareness of Potential Drug Interactions May Aid Avoidance. **Ther Drug Monitor** 1997;19:366-367.
127. Markowitz JS, Gill HS, DeVane CL, and Mintzer JE. Fluoroquinolone-mediated Inhibition of Clozapine Metabolism. **Am J Psychiatry** 1997;153:881.
128. Nemeroff CB, DeVane CL, Pollock BG. Effects of Antidepressants on the Cytochrome P450 System [letter]. **Am J Psychiatry** 1996;153:1656-1657.

129. DeVane CL. Rethinking Treatment Terminology. [letter]. **Am J Psychiatry** 1977;154:717.
130. DeVane CL, Spratt EG, Sallee FR. Psychoactive Drug-Drug Interactions in Children, Adolescents, and Adults. **Essential Psychopharmacology** 1997;2:33-50.
131. DeVane CL. Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. **Cellular & Molecular Neurobiology** 1999;19:443-466.
132. DeVane CL, Nemeroff CB. Psychotropic Drug Interactions. In: Robinson RG & Yates WR (Editors): **Psychiatric Treatment of the Medically Ill**, Marcel Dekker, Inc., 523-543, 1999.
133. Gill HS, DeVane CL, and Risch SC. Extrapyramidal Symptoms Associated with Cyclic Antidepressant Treatment: A Review of the Literature and Consolidating Hypotheses. **J Clin Psychopharmacology** 1997;17:377-389.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 22

134. DeVane CL, Markowitz JS, Hardesty SJ, Mundy S, Gill HS. Fluvoxamine-Induced Theophylline Toxicity. [letter] **Am J Psychiatry** 1997;154:1317-1318.
135. Markowitz JS, Gill HS, Hunt NM, Monroe RR, DeVane CL. Lack of Antidepressant--Cyclosporine Pharmacokinetic Interactions. **J Clin Psychopharmacol** 1998;18:91-93
136. DeVane CL. Translational Pharmacokinetics: Focus on Newer Antidepressants. **Anxiety & Depression** 8:(Suppl 1):64-70, 1998.
137. DeVane CL: Differential Pharmacology of Antidepressants. **J Clin Psychiatry** 1998;59(suppl 20):85-93.
138. DeVane CL: Clinical Implications of Dose-Dependent Cytochrome P-450 Drug Interactions with Antidepressants. **Human Psychopharmacology** 1998;13:329-336.
139. Markowitz JS, Morrison SD, and C. L. DeVane: Drug Interactions with Psychostimulants: A Review. **Int J Clin Psychopharmacol** 1999;14:1-18.
140. DeVane CL, Hill M, Antal EJ. Therapeutic Drug Monitoring of Alprazolam in Adolescent Asthmatics. **Ther Drug Monitor** 1998;20:257-260.

141. DeVane CL. Pills and Potions: Do the Best Drugs Come From Plants, Animals, or the Laboratory? **Med & Behav** 1998;1(1):37-38.
142. DeVane CL. Drug Efficacy versus Effectiveness. **Med & Behav** 1998;1(2):22-23.
143. Markowitz JS and DeVane CL. "**The Ritalin Handbook, What Every Parent and Patient Should Know**", 1st Edition. Morris Publishing, Kearney, NE. 2000;1-94.
144. DeVane CL. Drugs and Sexual Functioning. **Med & Behav** 1998;1(3):40-41.
145. DeVane CL. The Drug Development Process and Drug Information: How Much Do We Know? **Med & Behav** 1998;1(5):26.
146. DeVane CL. Marketing Prescription Drugs Directly to the Consumer. **Med & Behav** 1998;1(6): 16.
147. Upadhyaya HP and DeVane CL. Lack of Urinary Side-Effects with Nefazodone as Compared to Other Newer Antidepressants. **Hum Psychopharmacol** 1998;13:297-298.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 23

148. Markowitz JS and DeVane CL. Suspected Ciprofloxacin-Related Increase in Olanzapine Plasma Concentration. **J Clinical Psychopharmacol** 1999;19:289-290.
149. DeVane CL and Markowitz JS. "Drugs as Substrates of Metabolic Enzymes: Antipsychotics", In: ***Metabolic Drug Interactions***, René Levy, Editor, Lippincott-Raven Press, 2000, pp245-258.
150. Zhu H, Halaris A, Madakasira S, Pazzaglia P, Goldman N, DeVane CL, Andrew M, Reis D, and Piletz JE. Effect of Bupropion Treatment on Immunodensity of Putative Imidazoline Receptors on Platelets of Depressed Patients. **J Psychiatric Research** 1999;33:323-333.
151. DeVane CL: "No Mourning for the Conventional Antipsychotics: The Dawn of the Atypicals" (editorial). **Annals Pharmacotherapy** 1998;33:107-108.
152. DeVane CL and Nemeroff CB. Psychotropic Drug Interactions: 1998. **Primary Psychiatry** 1998;5:36-70.
153. DeVane CL, Ware MR, Emmanuel NP, Brawman-Mintzer O, Morton WA, Villarreal G, and Lydiard RB. Evaluation of The Efficacy, Safety and Physiological Effects of Fluvoxamine in Social Phobia. **Int J Clin Psychopharmacol** 1999;14:345-351.

154. DeVane CL and Pollock BG. Pharmacokinetic Considerations of Antidepressant Use in the Elderly. **J Clin Psychiatry** 1999;60(Suppl 20):38-44.
155. Goodnick PJ, Dominguez RA, DeVane CL, and Bowden CL. Bupropion Slow-Release Response in Depression: Diagnosis and Biochemistry. **Biological Psychiatry** 1998;44:629-632.
156. DeVane CL. Astemizole Interaction with Newer Antidepressants: A Closer Look. **Pharmacy Times** 1999; Feb,46-52.
157. DeVane CL, Boulton DW, Miller LF, and Miller RL. Pharmacokinetics of Trazodone and its Major Metabolite m-Chlorophenylpiperazine in Plasma and Brain of Rats. **International Journal of Neuropsychopharmacol** 1999;2:17-23.
158. Kelsey JE, DeVane CL, Zalski AH. Managing Depressive Disorders in Non-Elderly and Elderly Patients. (Interactive CD-ROM), Medical Communications Media, Inc., Langhorne, PA, December, 1998.
159. Markowitz JS and DeVane CL. Rifampin Induced Selective Serotonin Reuptake Inhibitor Withdrawal Syndrome in a Patient Treated with Sertraline. **J Clin Psychopharmacol** 20:109-110, 2000.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 24

160. DeVane CL. Pharmacology and Efficacy of Citalopram, a New SSRI: Formulary Considerations. **P & T** 1999;24:338-346.
161. Goodnick PJ, Puig A, DeVane CL, Freund B. Mirtazapine in Major Depression Combined with Comorbid Generalized Anxiety Disorder. **J Clin Psychiatry** 1999; 60:446-448..
162. Grothe DR, Calis KA, Jacobsen L, Kumra S, DeVane CL, Rapoport JL, Bergstrom RF, Kurtz DL. Olanzapine Pharmacokinetics in Pediatric and Adolescent Inpatients with Childhood Onset Schizophrenia. **J Clin Psychopharmacology** 2000; 20:220-225.
163. DeVane CL and Montano CB. Treatment of Depression in the Elderly. **Issues in Depression: Index & Reviews** 1999;1:4-5.
164. DeVane CL and Nemeroff CB. Psychotropic Drug Interactions: 1999. **Primary Psychiatry** 1999;6:39-88.
165. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine Related Death in a Child with Cytochrome P-450 2D6 Genetic Deficiency. **J Child Adolesc Psychopharmacol** 2000; 10:27-34.

166. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, and Risch SC. Effect of St. John's Wort (*Hypericum Perforatum*) on Cytochrome P-450 2D6 and 3A4 Activity in Healthy Volunteers. **Life Sciences** 2000;66:133-139.
167. DeVane CL, Simpkins JW, Boulton DW, Laizure SC, Miller RL. Analysis and Disposition of Morphine in Tissues of the Pregnant Rat and Foetus Following Acute and Continuous Intraperitoneal Administration to the Mother. **J Pharm Pharmacol** 1999; 51:1283-1287.
168. DeVane CL, Markowitz JS, Carson SW, Boulton DW, Gill HS, Nahas Z, and Risch SC. Single Dose Pharmacokinetics of Methylphenidate in CYP2D6 Extensive and Poor Metabolizers. **J Clin Psychopharmacology** 2000;20:347-349.
169. DeVane CL: "Cyclic Antidepressants", In: **Handbook of Pharmacokinetic and Pharmacodynamic Data**, 2nd ed., Murphy, J. (ed), American Society of Health Systems Pharmacists, Bethesda, MD, 2001;119-142.
170. DeVane CL and Markowitz JS. Avoiding Psychotropic Drug Interactions in the Cardiovascular Patient. **Menninger Clinic Bulletin** 2000; 64:49-59.
171. DeVane CL. Pharmacokinetics and Pharmacodynamics of Antidepressant Medication. **Am J Managed Care** 2000;6:(Suppl):39-46.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 25

172. Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS. Ethylphenidate Formation in Human Subjects After the Administration of a Single Dose of Methylphenidate and Alcohol. **Drug Metab Disp** 2000; 28:620-624.
173. DeVane CL, Pollock RB. Free Drug Fraction Versus Free Drug Concentration. **J Clin Psychiatry** 2000;61:449 [letter].
174. Dodd S, Boulton DW, Burrows GD, DeVane CL, Norman TR. Metabolism of mirtazapine enantiomers by recombinant human cytochrome P450 enzymes and human liver microsomes. **Hum Psychopharmacol Clin Exp** 2001;16:541-544.
175. DeVane CL. Characteristics of Ideal Antidepressants in the 21st Century. **J Clin Psychiatry** 2000;62[suppl 11]:4-8.
176. DeVane CL. "Commentary on the Tolerability and Safety of Newer Antidepressants" In: Sacchetti E & Spano PF (Eds.) **Fluvoxamine: Established and Emerging Roles in Psychiatric Disorders** (Advances in Preclinical and Clinical Psychiatry, Vol. 1), Excerpta Medica, Amsterdam, 2000; pp.

105-116.

177. DeVane CL. Interaction Potential of Selective Serotonin-Reuptake Inhibitors. **Am J Health Sys Pharm** [letter] 2000;57:1802.
178. Boulton DW, DeVane CL: Development and Application of a Chiral High Performance Liquid Chromatography Assay for Pharmacokinetic Studies of Methadone. **Chirality** 2000;12:681-687.
179. Risch SC, McGurk S, Horner MD, Nahas Z, Owens SD, Molloy M, Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J, George MS. A Case Report of the Use of Donepezil to Improve Cognition in a Schizoaffective Disorder Patient. **Neurocase** 2001;7:105-110.
180. Piletz JE, Zhu H, Madakasira S, Pazzaglia P, DeVane CL, Goldman N, Halaris A. Elevated P-Selectin on Platelets in Depression: Response to Bupropion. **J Psychiatr Res** 2000;34:397-404.
181. DeVane CL and Nemeroff CB. Psychotropic Drug Interactions: 2001. **Primary Psychiatry** (2001; in press).
182. DeVane CL: Substance P: A New Era, a New Role. **Pharmacotherapy** 2001;21:1061-1069.
183. DeVane CL and Nemeroff CB: Clinical Pharmacokinetics of Quetiapine An Atypical Antipsychotic **Clin Pharmacokinetics** 2001;40:509-522.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 26

184. Markowitz JS, DeVane CL, Liston HL, Montgomery SA: An Assessment of Selective Serotonin Reuptake Inhibitor Discontinuation Symptoms with Citalopram. **Int Clin Psychopharmacol** 2000;15:329-333
185. Liston HL, Markowitz JS, DeVane CL. Drug Glucuronidation in Clinical Psychopharmacology. **J Clin Psychopharmacol** 2001;21:500-515.
186. Goodnick PJ, Mendosa L, Kuman A, Freund B, DeVane CL. Sertraline and Diabetic Neuropathy: Response and Biology. **Psychosomatic Med** 2000;62:461-62.
187. Goodnick PJ, Breakstone K, Kumar A, Freund B, DeVane CL. Nefazodone in Diabetic Neuropathy: Response and biology. **Psychosomatic Med** 2000;62:599-600.
188. Markowitz JS, DeVane CL. Attention-deficit Hyperactivity Disorder (ADHD) and the Rise in Methylphenidate Use. **U.S. Pharmacist** 2000; suppl:3-10.

189. DeVane CL. Diagnosis of Depression and Advances in Antidepressant Pharmacotherapy. **Am J Health Sys Pharm** 2001; in press.
190. Boulton DW, Arnaud P, DeVane CL. Methadone Inhibits P-450 3A Activity in Healthy Volunteers as Assessed by the Urinary Cortisol Ratio. **Brit J Clin Pharmacology** 2001; 51:350-354.
191. DeVane CL, Liston HL. An Explanation of the Second Dose Effect in Pharmacokinetics and Its Application in Clinical Psychopharmacology. **Psychopharmacol Bull** 2001;35:42-52.
192. Markowitz JS, DeVane CL. The Emerging Recognition of Herb-Drug Interactions With St. John's Wort (*Hypericum Perforatum*). **Psychopharmacol Bull** 2001;35:53-64..
193. DeVane CL, Nemeroff CB. Evaluation of Risperidone Drug Interactions. **J Clin Psychopharmacol** 2001;21:408-416.
194. Liston HL, Markowitz JS, Hunt N, DeVane CL, Boulton DW, and Ashcraft E. Lack of Citalopram Effect on the Pharmacokinetics of Cyclosporine. **Psychosomatics** 2001;42:370-372.
195. Levin GL, Nelson LA, DeVane CL, Preston SL, Carson SW, Eisele G. A Pharmacokinetic Drug-Drug Interaction Study of Venlafaxine and Indinavir. **Psychopharmacol Bull** 2001;35:62-71.
196. DeVane CL, Markowitz JS, Liston HL, Risch SC. Charleston Antidepressant Drug Interactions Surveillance Program (CADISP). **Psychopharmacol Bull** 2001; 35:50-61.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 27

197. Boulton DW, Markowitz JS, and DeVane CL. Olanzapine Assay by High Performance Liquid Chromatography Using Ultraviolet Detection **J Chromatography** 2001;759:319-323.
198. DeVane CL and Grothe DR. Pharmacology of Antidepressants: Focus on Nefazodone. **J Clin Psychiatry** 2002;63(Suppl 1):10-17.
199. DeVane CL, and Boulton DW. Great Expectations in Stereochemistry. Focus on Antidepressants. **CNS Spectrums** 2002;7(suppl):28-33.
200. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, and Goldman J. Differential Time Course of Cytochrome P450 2D6 Enzyme Inhibition by Fluoxetine, Sertraline, and Paroxetine in Healthy Volunteers. **J Clin Psychopharmacol** 2002;22:169-173.
201. Tueth MJ, DeVane CL, and Evans DL: "Treatment of Psychiatric Emergencies", In: AF

Schatzberg & CB Nemeroff (Eds). **Essentials of Clinical Psychopharmacology**, APA Press, Inc., Washington, D.C., 2001; pp 589-599.

202. Boulton DW, Arnaud P, DeVane CL. Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers Following a Single Oral Dose of Racemate. **Clin Pharmacol Ther** 2001;70: 1-10.
203. Donovan JL and DeVane CL. A Primer on Caffeine Pharmacology and Its Drug Interactions in Clinical Psychopharmacology. . **Psychopharmacol Bull** 2001;35:30-48.
204. Markowitz JS, DeVane CL, Liston HL, Boulton DW, Risch SC. Probenecid Effects on the Disposition of Olanzapine and Risperidone in Healthy Volunteers. **Clin Pharmacol Ther** 2001;71:30-38.
205. DeVane CL, Marokwitz JS. Avoiding psychotropic drug interactions in the cardiovascular patient. **Economics of Neuroscience** 2001;3:68-71.
206. Markowitz JS, DeVane CL, Liston HL, Boulton DW, Risch SC. Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. **J Clin Pharmacol** 2002; 42:104-106.
207. DeVane CL, Liston HL, and Markowitz JS. Clinical Pharmacokinetics of Sertraline. **Clinical Pharmacokinetics** 2002;41:1247-1266.
208. Markowitz JS, Kellner CH, DeVane CL, Beale M, Folk J, Curns C. Intranasal sumatriptan in Post-ECT headache: Results from an open-label trial. **J ECT** 2001;17:280-283.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 28

209. Boulton DW, DeVane CL, Liston HL, and Markowitz JS. Human Recombinant P-Glycoprotein Specificity for Atypical Antipsychotics. **Life Sci** 2002;71:163-169.
210. DeVane CL and Markowitz JS. Psychoactive Drug Interactions With Pharmacotherapy for Diabetes. **Psychopharmacology Bull** 2002;32(2):40-52.
211. Halaris A, Zhu H, Ali J, Nasrallah A, DeVane CL, and Piletz JE. Apparent dose-dependent down regulation of platelet Imidazoline binding sites after bupropion treatment. **Int J Neuropsychopharmacol** 2002;5:37-46.
212. DeVane CL. Clinical Significance of Drug Plasma Protein Binding and Binding Displacement Drug Interactions. **Psychopharmacology Bull** 2002; 36(3):5-21.

213. Malcolm R, Book SW, Moak D, DeVane CL, Czepowicz V. Clinical Applications of Modafinil in Stimulant Abusers: Low Abuse Potential. **Am J Addictions** 2002;11:247-249.
214. DeVane CL and Nemeroff CB. 2002 Guide to Psychotropic Drug Interactions. **Primary Psychiatry** 2002;9:28-57.
215. Azzimonti F, Atchley DH, Morrison CA, Dodd S, Boulton DW, DeVane, and Arnaud P. One Step Purification of Alpha-1-acid Glycoprotein from Human Plasma. Fractionation of its Polymorphic Allele Products. **J Chromatography** 2003;784:33-38.
216. Donovan JL, Malcolm RJ, and DeVane CL. High-Performance Liquid Chromatography Assay for the Enantiomers of Modafinil in Human Serum **Ther Drug Monitoring** 2003;25:197-202.
217. Wang J-S, DeVane CL. Pharmacokinetics and Drug Interactions of the Sedative Hypnotics. **Psychopharmacology Bull** 2003;37:10-29.
218. DeVane CL: "Principles of Pharmacokinetics and Pharmacodynamics", In: AF Schatzberg & CB Nemeroff (Eds) **American Psychiatric Press Textbook of Psychopharmacology**, 3rd edition 2003, pp. 129-145. .
219. Donovan JL, DeVane CL, Chavin KD, Taylor RM, and Markowitz JS. Siberian ginseng (*Eleutherococcus senticosus*) Effects on CYP2D6 and CYP3A4 Activity in Normal Volunteers. **Drug Metab Disp** 2003; 31:519-522.
220. DeVane CL. Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR. **Psychopharmacology Bull** 2003;37(Suppl 1):29-41.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 29

221. Nahas Z, George MS, Horner MD, Markowitz JS, Li, X, Lorberbaum JP, Owens SD, McGurk S, DeVane CL, Risch SC. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study. **Neurocase** 2003;9:274-282.
222. Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Wang Y, Muniz R. Bioavailability of Two Modified-Release Methylphenidate Formulations in Normal Volunteers: Ritalin LA versus Concerta. **Clinical Pharmacokinetics** 2003;42:393-401.
223. Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary Levels of Quinine in Tonic

- Water Do Not Inhibit CYP2D6 *In Vivo*. **Food Chem Toxicology** 2003;41:1199-1201.
224. Wang J-S, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-Methadone *In Vitro*. **Drug Metab Disp** 2003;31:742-747.
225. Markowitz JS, Donovan JL, DeVane CL, Chavin KD, Spikes L. *Gingko Biloba* Has No Effect On the Cytochrome P-450 2D6 and Marginal Effects of CYP3A4 Activity in Normal Volunteers. **J Clin Psychopharmacol** 2003;23:676-681.
226. Markowitz JS, DeVane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (*Allium sativum L*) supplementation on cytochrome P450 2D6 and 3A4 activity in normal volunteers. **Clin Pharmacol Ther** 2003;74:170-177.
227. DeVane CL. Immediate-Release Versus Controlled-Release Formulations: Pharmacokinetics of Newer Antidepressants in Relation to Nausea. **J Clin Psychiatry** 2003;64(suppl 18):14-19.
228. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L. Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers. **J Clin Psychopharmacol** 2004;24:4-10.
229. DeVane CL. "Cyclic Antidepressants", In: Burton M, Evans WE, Schentag JJ, Shaw L (eds), **Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring, 4th ed**, Williams & Wilkins, Baltimore, MD, 2006 pp781-797.
230. DeVane CL and Mintzer J. Risperidone in the Management of Psychiatric and Neurodegenerative Disease in the Elderly: An Update. **Psychopharm Bull** 2003; (in press).

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 30

231. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang J-S, Chavin KD. St. John's wort (*Hypericum perforatum*) alters hepatic drug metabolism by induction of CYP3A4. **JAMA** 2003;290:1500-1504 .
232. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang J-S, Chavin KD. Multiple-doses of Saw Palmetto (*Serenoa repens*) did not alter CYP2D6 and CYP3A4 activity in normal volunteers **Clin Pharmacol Ther** 2003;74:536-542.

233. DeVane CL. Pharmacokinetics, Drug Interactions, and Tolerability of Valproate **Psychopharm Bull** 2003;37(Supplement 2):25-42.
234. Wang J-S, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain Penetration of Methadone (R)- and (S)-enantiomers is Greatly Increased by P-glycoprotein Deficiency in the Blood Brain Barrier of *Abcb1a* Gene Knockout Mice. **Psychopharmacology** 2004;173:132-138.
235. Wang J-S, Taylor R, Ruan Y, Donovan JL, Markowitz JS, DeVane CL. Olanzapine Penetration into Brain is Greater in Transgenic *Abcb1a* P-glycoprotein Deficient Mice than FVB1 (Wild Type) Animals. **Neuropsychopharmacology** 2004;29:551-557.
236. Wang J-S, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The Brain Entry of Risperidone and 9-Hydroxy-Risperidone is Greatly Limited by P-glycoprotein. **Int J Neuropsychopharmacol** 2004;7:415-419.
237. Donovan JL, DeVane CL, Malcolm RJ, Mojsiak J, Chiang N, Elkashef A, Taylor RM. Modafinil Influences the Pharmacokinetics of Intravenous Cocaine in Healthy Cocaine-Dependent Volunteers **Clin Pharmacokinetics** 2005;44:753-765..
238. Donovan JL, DeVane CL, Lewis JG, Wang J-S, Ruan Y, Chavin KD, Markowitz JS. Effects of St. John's wort (*Hypericum perforatum*) on Plasma Androgen Concentrations in Healthy Men and Women: A Pilot Study (submitted, 2004).
239. Markowitz JS, Donovan JL, DeVane, CL, Chavin KD. Common herbal supplements did not produce false positive results on urine drug screens analyzed by enzyme immunoassay. **J Anal Toxicol** 2004;28:72-273.
240. Loughhead AM, Stowe ZN, Ritchie JC, Newport DJ, DeVane CL, Owens MJ. Placental passage of tricyclic antidepressants. **Am J Obstet Gynecol** (2004; in press).

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 31

241. Donovan JD, DeVane CL, Chavin KD, Wang J-S, Gibson BB, Gefroh HA, Markowitz JS. Multiple Nighttime Doses of Valerian (*Valeriana officinalis*) had Minimal Effects on CYP3A4 Activity and No Effect on CYP2D6 Activity in Healthy Volunteers. **Drug Metab Disp** 2004;32:1333-1336.
242. Donovan JL, Chavin KD, DeVane CL, Taylor RM, Wang J-S, Ruan Y, Markowitz JS. Green Tea (*Camellia Sinensis*) Extract Does Not Alter Cytochrome P450 3A4 or 2D6 Activity in Healthy Volunteers. **Drug Metab Disp** 2004;32:906-908.

243. Donovan JL, DeVane CL, Lewis JG, Chavin KD, Wang J-S, Ruan Y, Markowitz JS. Effects of St. John's wort (*Hypericum perforatum*) on plasma androgen concentrations in healthy men and women: A pilot study. **Phytotherapy Res** (2005; in press).
244. Markowitz JS, DeVane CL, Lewis JG, Chavin KD, Wang JS, Donovan JL. The effect of a Ginkgo biloba extract on plasma steroid concentrations in normal volunteers: A pilot study. **Pharmacotherapy** (in press, 2005).
245. Wang JS, Markowitz JS, Donovan JL, DeVane CL. P-glycoprotein Does Not Actively Transport Nicotine and Cotinine. **Addiction Biology** 2005;10:127-129.
246. Winter HR, DeVane CL, Figueroa C, Ennis DJ, Hamer JE, Davis PC, Smith MA. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. **J Clin Psychopharmacol** 2005; in press.
247. DeVane CL. Antidepressant Drug Interactions Are Potentially But Rarely Clinically Significant. **Neuropsychopharmacology** (in press, 2005).
248. Donovan JL, DeVane CL, Chavin KD, Oates JC, Njoku C., Patrick KS, Riorini RN, Markowitz SJ. Oral administration of a decaffeinated green tea (*Camellia sinensis*) extract did not alter urinary 8-epi-prostaglandin F₂alpha, a biomarker for in vivo lipid peroxidation. **J Pharmacy Pharmacology** 2005;57:1-5.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 32

Research Abstracts

1. DeVane CL and Culpepper WC: Retention of Technetium 99m Labeled Human Albumin Microspheres in Plastic Syringes. Presented at the American Society of Hospital Pharmacists' Midyear Clinical Meeting, Atlanta, GA, December 7-11, 1977.

2. DeVane CL: Drug Interactions Involving Psychotherapeutic Agents. Presented at the Association of Faculties of Pharmacy of Canada 36th Annual Research Meeting, Sarnia, Ontario, May 21-22, 1979.
3. DeVane CL, Sutfin TA, Savett M, and Jusko WJ: First-Pass Formation of Hydroxylated Metabolites of Imipramine and Desipramine. Presented at the 12th Congress, Collegium Internationale Neuro-Psychopharmacologicum, Goteborg, Sweden, June 22-26, 1980.
4. DeVane CL and Jusko WJ: Plasma Concentration Monitoring of Hydroxylated Metabolites of Imipramine and Desipramine, American College of Clinical Pharmacy, Boston, MA, July 24-26, 1980, **Drug Intell Clin Pharm** 14:633, 1980.
5. DeVane CL, Sawyer WP, Wilson JA, and Walker RD: Imipramine and Metabolite Concentrations in Enuretic Children, American Society of Clinical Pharmacology and Therapeutics, Orlando, Florida, March 17-20, 1982, **Clin Pharmacol Ther** 31:217, 1982.
6. Sutfin TA, DeVane CL, Savett M, and Jusko WJ: Pharmacokinetics of Imipramine and Its Major Active Metabolites in Man, American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Las Vegas, April, 1982.
7. Carson S and DeVane CL: Development of Analytical Methods for Plasma Concentration Monitoring of Second Generation Antidepressants, Thirteenth Annual Southeastern Conference for Post Graduate Pharmacy Education and Training, Athens, GA, March 5-7, 1982.
8. DeVane CL, Simpkins JW, Stout SA, and Field FP: Pharmacokinetics of Imipramine and Its Major Metabolites in the Pregnant Rat, Second World Congress of Clinical Pharmacology and Therapeutics, Washington, DC, July 31-August 5, 1983.
9. DeVane CL, Stout SA, and Simpkins JW: Development and Application of a Tissue Assay for Anticonvulsant Disposition in the Pregnant Rat, American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Miami, FL, November 1983.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 33

10. DeVane CL, Laizure SC, Phillips EW, and Birkhimer LJ: PSYKINFO: An International Computerized Data Base for Retrieving Pharmacokinetic Information on Psychoactive Drugs, 14th Congress, Collegium Internationale Neuropsychopharmacologicum, Florence, Italy, June 19-23, 1984.
11. Curry SH, DeVane CL, and Wolfe MM: Analysis, Pharmacokinetics and Physiological Effects of

- Amitriptyline in Healthy Volunteers Given Single 50 mg Oral Doses, 14th Congress, Collegium Internationale Neuropsychopharmacologicum, Florence, Italy, June 19-23, 1984.
12. Laizure SC and DeVane CL: Stability of Bupropion and Its Major Metabolites in Human Plasma Under Varying pH and Temperature Storage Conditions. **Drug Intell Clin Pharm** 19:447, 1985.
 13. DeVane CL, Laizure SC, Stewart JT, Dommissie CS, and Lai AA: Pharmacokinetics of Bupropion and Its Major Basic Metabolites in Normal Volunteers, Society of Biological Psychiatry, Dallas, Texas, May 15-19, 1985.
 14. Golden RN, DeVane CL, Rudorfer MV, Sherer MA, Laizure SC, Linnoila M, and Potter WZ: Bupropion Metabolites, HVA, and Clinical Response, American Psychiatric Association, Dallas, Texas, May 18-24, 1985.
 15. Golden RN, DeVane CL, Laizure SC, Rudorfer MV, and Potter WZ: Bupropion Metabolites in Plasma and CSF: Relationship to Clinical Effects. Society of Biological Psychiatry, Dallas, Texas, May 15-19, 1985.
 16. Curry SH, DeVane CL, and Wolfe MM: Pharmacology of Combined Antidepressant/H₂ Blocking Drug Therapy, New Clinical Drug Evaluation Unit Program (NCDEU), Key Biscayne, FL, May 1-3, 1985.
 17. DeVane CL and Laizure SC: Dose-Concentration Relationships in Plasma and Brain of Bupropion and its Major Metabolites in an Animal Model of Renal Failure. **Drug Intell Clin Pharm** 20:452, 1986.
 18. Curry SH, DeVane CL, and Wolfe MM: Lack of Interaction Between Ranitidine and Amitriptyline. World Congress on Clinical Pharmacology and Therapeutics, Stockholm, Sweden, July 1986.
 19. DeVane CL, Laizure SC, and Lai AA: Disposition of Bupropion in Normal Volunteers and Subjects With Alcoholic Liver Disease. Presented at 15th Congress, Collegium Internationale Neuro-Psycho Pharmacologicum, San Juan, P.R., December 14-17, 1986.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 34

20. Meyers EM, Ruttener AJ, Hearn L, Judkins J, Nguyen M-TT, Miller RL, and DeVane CL: Benzoyltropine and Tropacocaine: Epidemiological and Biochemical Evidence for Cholinergic Activity in These Cocaine-Impurities. Society for Neuroscience, 1987.
21. Kantor RJ, DeVane CL, and Epstein ML: Electrophysiologic Effects of High-Dose Intravenous Cocaine in Dogs. American Heart Association, Anaheim, CA, November 16, 1987.

22. Grasela TH, DeVane CL, Hill M, and Antal EJ: Postmarketing surveillance of alprazolam population pharmacokinetics. American College of Clinical Pharmacy, Philadelphia, PA, July 26, 1988; **Pharmacotherapy 8:135,1988.**
23. Burchfield DJ, Abrams RM, Miller RL, and DeVane CL: Pharmacokinetics and pharmacodynamics of cocaine in pregnant sheep. American Pediatric Society, Anaheim, CA, May 1988.
24. Lim C, DeVane CL, Tingle D, Hackett L, and Carson S: Effects of Electroconvulsive Therapy (ECT) on Serum Alpha-1-Acid Glycoprotein - American College of Clinical Pharmacy, Philadelphia, PA, July 26, 1988; **Pharmacotherapy 8:135,1988.**
25. DeVane CL, Grasela TH, and Antal EJ: Clinical Pharmacokinetic Database for Alprazolam Using Limited Sampling. Collegium Internationale Neuro-Psycho Pharmacologicum, Munich, F.R.G., August 18, 1988; **Psychopharmacology 96(5):321, 1988.**
26. Delafuente JC, DeVane CL, and Miller RL: Immunomodulation by Cocaine and Its Major Metabolite, American College of Clinical Pharmacy, Kansas City, August 9, 1989; **Pharmacotherapy 9:136,1989.**
27. DeVane CL, Lim C, Carson SW, Tingle D, Hackett L, and Ware MR: Effect of Serial ECT on Serum Concentration of Alpha-1-Acid Glycoprotein and Cortisol. **Society of Biological Psychiatry**, New York, May 10, 1990; **Biol Psychiat 27(9A):63, 1990.**
28. Delafuente JC and DeVane CL: Immunologic Effects of Cocaine and Other Tropane Alkaloids. American Academy of Allergy and Immunology, Baltimore, March 27, 1990.
29. DeVane CL, Miller LF, and Miller RL: Pharmacokinetics of Trazodone and MCPP in Rats. Collegium Internationale Neuropsychopharmacology, Kyoto, Japan, Sept. 11, 1990.
30. DeVane CL, Miller RL, Kempf J, and Levin G: Development of an HPLC Assay for Plasma GABA and Application in Child Psychiatry. European College of Neuropsychopharmacology, Monte Carlo, Monaco, **Eur Neuropsychopharm**, 1:467, 1991.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 35

31. Kempf JP, DeVane CL, and Levin GL: Plasma GABA Levels in Aggressive Children Treated With Clonidine. **Proceedings of the American Association of Child and Adolescent Psychiatry**, 7:74, 1991.
32. Potter WE, DeVane CL, and Rudorfer MV: Study-State Predictions Based on First Dose Data. Collegium Internationale Neuropsychopharmacology, Nice, France. July 1, 1992; **Clin**

Neuropharmacol, 15 (Supp A):239-240, 1992.

33. Nadeau SE, Couch MW, DeVane CL, and Shukla SS: A Regional Analysis of D2-Dopamine Receptors in Parkinson's Disease Using [¹²³I]-Iodobenzamine SPECT. American Academy of Neurology, 1994.
34. Risch SC, Jackson C, Ware M, Rooney K, Tyson S, and DeVane L: Case Reports of Combined Clozapine and Risperidone Pharmacotherapy: Pharmacokinetic and Pharmacodynamic Interactions. American College of Neuropsychopharmacology, 33rd Annual Meeting, San Juan, PR, Dec 16, 1994.
35. DeVane CL: Comparative Safety and Tolerability of Selective Serotonin Reuptake Inhibitors. European Conference on SSRI Differentiation, Amsterdam, April 30, 1995.
36. DeVane CL: Comparative Safety and Tolerability of SSRIs. European Conference on SSRI Differentiation, Lake Como, Italy, September 29, 1995.
37. DeVane CL, Ware MR, Emmanuel NP, Brawman-Mintzer O, Johnson MR, Ruby RN, Villarreal G, and Lydiard RB: The Evaluation of the Safety, Efficacy, and Physiological Effects of Fluvoxamine in Social Phobia. American College of Neuropsychopharmacology, 34th Annual Meeting, San Juan, PR, December 12, 1995.
38. DeVane CL, Ware MR, Emmanuel NP, Brawman-Mintzer O, Jones CR, Morton WA, Kapp R, Villarreal G, and Lydiard RB: The Evaluation of Fluvoxamine in Social Phobia. American Psychiatric Association, New York, May 7, 1996.
39. DeVane CL: Theoretical Considerations of Dose/Concentration/Effect Relationships: Direct and Indirect Pharmacokinetic/Dynamic Models. CINP, Melbourne, Australia, July, 1996. **Eur Neuropsychopharmacol** 6(Suppl 3):81-82, 1996.
40. DeVane CL, Ware MR, Emmanuel NP, and Lydiard RB: The Evaluation of the Safety, Efficacy, and Physiological Effects of Fluvoxamine in Social Phobia. ECNP, Amsterdam, October 24, 1996. **Eur Neuropsychopharmacol** 6(Suppl 4):153, 1996.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 36

41. DeVane CL: Comparative Safety and Tolerability of SSRIs. 9th ECNP Congress, Amsterdam, October 21, 1996.
42. DeVane CL, Markowitz JS, & Gill HS. Charleston Drug Interactions Surveillance Program. American Psychiatric Association, Annual Meeting, San Diego, May 18, 1997.

43. DeVane CL: Psychopharmacology in HIV Positive Patients. World Congress of Psychiatry, Nice, France, June 25, 1997.
44. DeVane CL: Pharmacology and Pharmacokinetics of the Benzodiazepines Relevant to Use in Cardiac Patients. Asian Cardiac Anxiety Awareness Program, Bangkok, Thailand, July 22, 1997.
45. DeVane CL, Gill HS, Sallee FR, Markowitz JS, and Hand L. The Pharmacogenetics of Methylphenidate. Am Coll Clin Pharm, Annual Meeting, Phoenix, AZ, November 9-12, 1997.
46. DeVane CL, Markowitz JS, Gill HS, Nahas Z, and Risch SC. Charleston Drug Interactions Surveillance Program, American College of Neuropsychopharmacology Annual Meeting, Kamuela, Hawaii, December 9, 1997.
47. Piletz JE, Halaris A, Pazzaglia P, Madakasira S, Zhu H, Feng Y DeVane CL, Andrew M. Up-regulation of platelet I₁-imidazoline receptors in depression and normalization following bupropion treatment. Int Congress of Pharmacology, Munich, Germany July 26, 1998.
48. DeVane CL, Markowitz JS, Gill HS, Carson SW, Sallee FR, Boulton DW, Patrick KS. The Effect of Methylphenidate on Cytochrome 2D6 and 3A4. International College of Neuropsychopharmacology (CINP), Glasgow, Scotland, July 13, 1998, **Int J Neuropsychopharmacol** 1999;2(Suppl 1), p63.
49. Zhu H, Halaris A, Madakasira S, Pazzaglia P, Goldman N, DeVane CL, Andrew M, Piletz JE. Effect of Bupropion Treatment on Immunodensity of Putative Imidazoline Receptors on Platelets of Depressed Patients. Society for Neuroscience, 28th Annual Meeting, Los Angeles, Nov 8, 1998.
50. Halaris A, Zhu H, Madakasira S, Pazzaglia P, Goldman N, DeVane CL, Andrew M, Piletz J. Imidazoline Receptor Antiserum-Selected Protein May Be A State Marker For Depression. Third International Symposium on Imidazoline Receptors, Bonn, Germany, July 22, 1998.
51. Goodnick P, Puig A, DeVane CL. Mirtzapine in Combined Major Depression and Genralized Anxiety Disorder. Society of Biological Psychiatry, 53rd Annual Meeting, Toronto, CA, May 27, 1998; **Biol Psychiatry** 1998;43:99S.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 37

52. Goodnick P, Puig A, DeVane CL. Mirtzapine in Combined Major Depression and Genralized Anxiety Disorder. International College of Neuropsychopharmacology (CINP), Glasgow, Scotland, July 13, 1998, **Int J Neuropsychopharmacol** 1999;2(Suppl 1), p48.

53. Goodnick P, Lopez L, Bowden C, DeVane CL. Bupropion in Atypical Depression. New Clinical Drug Evaluation Unit Program, 38th Annual Meeting, Boca Raton, FL, June 10-13, 1998, # 190.
54. S.C. Risch, Z. Nahas, M. Molloy, S.D. Owens, M.Hamner, C.L. DeVane, & M.S. George. An MRI Volumetric Study of Caudate Volume Before and After Atypical Antipsychotics in Schizophrenic Patients. American College of Neuropsychopharmacology Annual Meeting, Las Croabas, PR, Dec. 1998.
55. C.L. DeVane, J.S. Markowitz, H.S. Gill, S.W. Carson, F.R.Sallee, D.W. Boulton, Z.Nahas, & S.Craig Risch. Methylphenidate Effects on Cytochrome (CYP)2D6/3A4 in Children and Disposition in CYP2D6 Poor and Extensive Metabolizers. American College of Neuropsychopharmacology Annual Meeting, Las Croabas, PR, Dec. 1998.
56. J.S. Markowitz, C.L. DeVane, H.S. Gill, S.W. Carson, F.R.Sallee, D.W. Boulton, Z.Nahas, & S.Craig Risch. Methylphenidate Effects on Cytochrome (CYP)2D6/3A4 in Children and Disposition in CYP2D6 Poor and Extensive Metabolizers. College of Psychiatric and Neurologic Pharmacists, 2nd Annual Meeting, Lake Tahoe, March 25, 1999.
57. J.S. Markowitz and C.L. DeVane. Effects of Abrupt Discontinuation of Citalopram. American Psychiatric Association Annual Meeting, Washington, D.C. May 20, 1999.
58. Risch SC, Nahas ZH, Hamner MB, Molloy M, DeVane CL, Owens SD, George MS. MRI Volumetric Studies of Atypical Antipsychotics. American Psychiatric Association, Annual Meeting, Washington, D.C., May 18, 1999.
59. Goodnick PJ, Mendosa L, Freund B, Kuman A, DeVane CL. Biology of Sertraline in Diabetic Neuropathy. American Psychiatric Association, Annual Meeting, Washington, D.C., May 20, 1999.
60. Goodnick PJ, Breakstone K, Freund B, Kuman A, DeVane CL. Biology of Nefazodone in Diabetic Neuropathy. American Psychiatric Association, Annual Meeting, Washington, D.C., May 20, 1999.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 38

61. D.W. Boulton, C.L. DeVane, P. Arnaud, Z. Nahas. Pharmacokinetics and Dynamics of Methadone Enantiomers Following a Single Oral Dose to Healthy Female Volunteers. College on Problems of Drug Dependence, Annual Meeting, Acapulco, Mexico, June 14, 1999; **NIDA Research Monograph No. 180**, 2000; p. 153.

62. J.S. Markowitz and C.L. DeVane. Effects of Abrupt Discontinuation of Citalopram. European College of Neuropsychopharmacology Annual Meeting, London, England, September 22, 1999.
63. J.S. Markowitz, C.L. DeVane, S.W. Carson, Z. Nahas, Boulton D.W., K. Chike-Harris, J.W.W. Leung, S.C. Risch, Effect of St. John's Wort on Cytochrome (CYP) P-450 Activity in Healthy Volunteers. European College of Neuropsychopharmacology Annual Meeting, London, England, September 24, 1999.
64. J.S. Markowitz, C. L. DeVane, D.W. Boulton, Z. Nahas, S.C. Risch, K.S. Patrick, J. Goldman. Ethylphenidate Formation After Administration of Methylphenidate and Ethanol. American College of Neuropsychopharmacology, Acapulco, Mexico, December 13, 1999.
65. S.C. Risch, Z. Nahas, M.D. Horner, S.R. McGurk, M. Molloy, J. Goldman, C. Gillard, S.D. Owens, S. Chrstie, J.S. Markowitz, C.L. DeVane, J. Mintzer, M.S. George. Donepezil Augmentation of Antipsychotics in Schizophrenia: Cognitive and fMRI Effects. American College of Neuropsychopharmacology, Acapulco, Mexico, December 13, 1999.
66. Goldman J, Nahas Z Palecko S, Kelly S, DeVane CL, Mintzer J, George MS, Risch SC. Donepezil Augmentation for Cognitive Impairment in Euthymic Bipolar Disorder. Society of Biological Psychiatry, Annual Meeting, Chicago, IL, May 10, 2000.
67. J.S. Markowitz, C. L. DeVane, D.W. Boulton, Z. Nahas, S.C. Risch, K.S. Patrick, J. Goldman. Ethylphenidate Formation After Administration of Methylphenidate and Ethanol. College of Psychiatric and Neurologic Pharmacists, 3rd Annual Meeting, Washington, DC April 6-9, 2000.
68. Markowitz JS, Kellner CH, DeVane CL, Beale MD, Folk JW, Burns C, Myers M. Intranasal Sumatriptan for the Treatment of Post-ECT Headache. College of Psychiatric and Neurologic Pharmacists, 3rd Annual Meeting, Washington, DC April 6-9, 2000.
69. Liston HL, DeVane CL, Boulton DW, Markowitz JS, Goldman J, Risch SC. Time Course of Enzyme Inhibition of Fluoxetine vs. Sertraline vs. Paroxetine. College of Psychiatric and Neurologic Pharmacists, 3rd Annual Meeting, Washington, DC April 6-9, 2000.
70. Levin GM, Nelson LA, DeVane CL, Preston SL, Carson SW, Eisele G. Venlafaxine and Indinavir: Results Of A Pharmacokinetic Interaction Study. College of Psychiatric and Neurologic Pharmacists, 3rd Annual Meeting, Washington, DC April 6-9, 2000.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 39

71. Liston HL, Markowitz JS, Hunt N, DeVane CL. Effect of Citalopram on Cyclosporine Concentrations in Heart Transplant Patients. College of Psychiatric and Neurologic Pharmacists, 3rd Annual Meeting,

Washington, DC April 6-9, 2000.

72. Markowitz JS, Kellner CH, DeVane CL, Beale MD, Folk JW, Burns C, Myers M. Intranasal Sumatriptan for the Treatment of Post-ECT Headache. American Psychiatric Association Annual Meeting, Chicago, IL, May 15, 2000.
73. Liston HL, DeVane CL, Boulton DW, Markowitz JS, Goldman J, Risch SC. Time Course of Enzyme Inhibition of Fluoxetine vs. Sertraline vs. Paroxetine. International College of Neuropsychopharmacology (CINP), Brussels, Belgium, July 12, 2000; **Int J Neuropsychopharmacol** 3(Suppl 1):183, 2000.
74. Piletz JE, Zhe H, Madakasira S, Pazzaglia P, Goldman N, DeVane L. Platelet procoagulant state and imidazoline binding sites are increased in depression and not normalized with bupropion. International College of Neuropsychopharmacology (CINP), Brussels, Belgium, July 12, 2000; **Int J Neuropsychopharmacol** 3(Suppl 1):196, 2000.
75. Dodd S, Boulton DW, Burrows GD, DeVane CL, Norman TR. Metabolism of enantiomers of mirtazapine by recombinant human cytochrome P450 enzymes and human liver microsomes. International College of Neuropsychopharmacology (CINP), Brussels, Belgium, July 13, 2000; **Int J Neuropsychopharmacol** 3(Suppl 1):213, 2000.
76. DeVane CL, Boulton DW, Liston HL, Markowitz JS. Human Recombinant P-Glycoprotein Specificity for Atypical Antipsychotics. American College of Neuropsychopharmacology Annual Meeting (ACNP), San Juan, P.R., Dec 12, 2000.
77. Nahas Z, Risch SC, Horner MD, Markowitz JS, Xingbao L, Ldorberbaum JP, McGurk S, DeVane CL, George MS. Augmenting an Atypical Antipsychotic with a Cognitive Enhancer (Donepezil) Improves Regional Brain Activity In Schizophrenia Patients: A Double-blind Placebo Controlled BOLD phMRI Study. Society of Biological Psychiatry, Annual Meeting, New Orleans, May 1-4, 2001; **Biol Psych** 2001;49:29S
78. Nahas Z, Risch SC, Horner MD, Markowitz JS, Xingbao L, Ldorberbaum JP, McGurk S, DeVane CL, George MS. Augmenting an Atypical Antipsychotic with a Cognitive Enhancer (Donepezil) Improves Regional Brain Activity In Schizophrenia Patients. ACNP, 2000
79. Piletz JE, Zhu H, Madakasira S, DeVane L, Halaris A. Platelet Procoagulant State is Increased in Depression and Not normalized by Bupropion Treatment. American College of Neuropsychopharmacology Annual Meeting (ACNP), San Juan, P.R., Dec 12, 2000.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 40

80. DeVane CL, Boulton DW, Arnaud P. Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers Following A Single Oral Dose of Racemate. American Society of Clinical Pharmacology and Therapeutics, Annual Meeting, Orlando, FL March 12, 2001.
81. Markowitz JS, DeVane CL, Liston HL, Boulton DW, Risch SC. Probenecid Effects on the Disposition of Olanzapine and Risperidone. American Psychiatric Association annual meeting, New Orleans, May 6, 2001
82. Markowitz JS, DeVane CL, Liston HL, Boulton DW, Risch SC. Probenecid Effects on the Disposition of Olanzapine and Risperidone. NCDEU, Scottsdale, AZ, May 30, 2001.
83. Liston HL, Markowitz JS, DeVane CL, Boulton DW, Ashcraft E, Hunt N. Lack of Citalopram-Cyclosporine Interaction. Society of Biological Psychiatry, Annual Meeting, New Orleans, May 1-4, 2001; **Biol Psych** 2001;49:29S.
84. Markowitz JS, DeVane CL, Liston HL, Boulton DW, Risch SC. Probenecid Effects on the Disposition of Olanzapine and Risperidone. APA Institute on Psychiatric Services, Orlando, FL. October 12, 2001.
85. Markowitz JS, DeVane CL, Liston HL, Boulton DW, Risch SC. Probenecid Effects on the Disposition of Olanzapine and Risperidone. American College of Clinical Pharmacy Annual Meeting, Tampa, FL September 23, 2001.
86. DeVane CL, Liston HL, Donovan JL, Markowitz JS, Cheng KT, Risch SC, and Willard L. Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone. XXIII CINP Congress, Montreal, June 27, 2002; **Int J Neuropsychopharm** 2002;5:(Suppl 1):105.
87. Markowitz JS, DeVane CL, Donovan JL, Risch SC. An Assessment of CYP2D6 Inhibitory Effects of Ginko Biloba in Normal Volunteers. XXIII CINP Congress, Montreal, June 27, 2002; **Int J Neuropsychopharm** 2002;5:(Suppl 1):192.
88. Markowitz JS, DeVane CL, Donovan JL, Risch SC, Emmanuel N. An Assessment of the Potential for Common Herbal Supplements to Cause False Positive Results on the Enzyme Immunoassay (EIA) Urine Drug Screen. Annual Meeting College of Psychiatric and Neurologic Pharmacists (CPNP), Seattle WA, April 18-21, 2002.
89. Malcolm RJ, Donovan JL, DeVane CL, Elkashef A, Chiang N, Mojsiak J. Influence of Modafinil, 4000 or 800 mg/day on Subjective Effects of Intravenous Cocaine in Non-treatment Seeking Volunteers. College on Problems of Drug Dependence, Quebec City, Canada, June 8-13, 2002.

CURRICULUM VITAE

C. LINDSAY DEVANE

PAGE 41

90. Donovan JL, Malcolm RJ, DeVane CL. Development and Application of a Chiral Assay for the *d*- and *l*- Isomers of Modafinil in Serum. College on Problems of Drug Dependence, Quebec City, Canada, June 8-13, 2002.
91. DeVane CL, Donovan JL, Liston H, Markowitz JS, Risch C, Willard L. Lack of Venlafaxine CYP3A4 Inhibitory Effects on Oral and IV Model Substrates. European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 6, 2002; **Eur Neuropsychopharmacol** 2002;12(Suppl 3):229.
92. Thomson MR, Dowd JJ, Markowitz JS, DeVane CL, Patrick KS. Enantioselective Transesterification of Methylphenidate to Ethylphenidate After Coadministration with Ethanol. American College of Clinical Pharmacology, Annual Meeting, San Francisco, CA, September 21-27, 2002; **J Clin Pharmacol** 2002;42:1069.
93. Wang J-S, DeVane CL. *In Vitro* Reaction Phenotyping of (R)- and (S)- Methadone Using a Substrate Depletion Approach. American College of Neuropsychopharmacology Annual Meeting (ACNP), San Juan, P.R., Dec 8-12, 2002.
94. DA Sclar, TL Skaer, LM Robison, MW Dickson, CL DeVane, JS Markowitz. Factors influencing the Prescribing of Atypical Antipsychotic Pharmacotherapy. Does Age Matter? The International Psychogeriatric Association European Regional Meeting, Geneva, April 1-4th, 2003.
95. SC Risch, MD Horner, SR McGurk, S Palecko S, JS Markowitz, Nahas Z, Christie SD, DeVane CL. Donepezil Supplementation to Improve Cognition in Schizophrenia. American College of Neuropsychopharmacology (ACNP) 41st Annual Meeting, San Juan, Puerto Rico, December 8-12th, 2002.
96. DA. Sclar LM, Robison, TL. Skaer, JS. Markowitz, CL, DeVane, WM Dickson, MA. Evans Cost of Use Patterns For Atypical Antipsychotics Among Medicaid Beneficiaries in the U.S. Annual Meeting of the British Royal College of Psychiatrists. Edinburgh, Scotland. July 1, 2003.
97. DA. Sclar LM, Robison, TL. Skaer, JS. Markowitz, CL, DeVane, WM Dickson, MA. Evans Use Patterns for Antipsychotics Among Medicaid Beneficiaries. American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003.
98. DA. Sclar LM, Robison, TL. Skaer, JS. Markowitz, CL, DeVane, WM Dickson, MA. Evans Cost of Use Patterns for Atypical Antipsychotics Among Medicaid Beneficiaries. American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003.

CURRICULUM VITAE
C. LINDSAY DEVANE

PAGE 42

99. DeVane CL, Wang J-S, Millicovsky G, Pennick M, Mays D, McDaniel C, Michaels A. Effects of Amphetamine and Methylphenidate on Cytochrome P450 Activity. American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003.
100. Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R. Pharmacokinetics of Methylphenidate After Oral Administration of Two Modified-Release Formulations in Healthy Adult Volunteers. American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003.
101. Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (*Eleutherococcus senticosus*) Effects on CYP2D6 and CYP3A4 Activity in Normal Volunteers. American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003.
102. Markowitz JS, Donovan JL, DeVane CL, Sipkes L, Chavin KD, Taylor RM. Ginkgo biloba has no effect on cytochrome P-450 2D6 and Marginal effects on 3A4 activity in normal volunteers. American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003.
103. Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R. Bioavailability of two long-acting formulations of methylphenidate. NIMH sponsored 43rd Annual NCDEU Meeting, Boca Raton, FL. May 27-30, 2003.
104. Sclar DA, Skaer TL, Robison LM, Dickson WM, Markowitz JS, DeVane CL. Use and Cost Patterns of Risperidone versus Olanzapine for the Treatment of Schizophrenia: An Assessment of Medicaid Children and Adolescents Age 5-18 Years. European College of Neuropsychopharmacology (ECNP), Prague, Sept. 19, 2003.
105. Sclar DA, Skaer TL, Robison LM, Markowitz JS, DeVane CL. Use and Cost Patterns of Risperidone versus Olanzapine for the Treatment of Schizophrenia Among U.S. Children and Adolescents 5-18 Years Old. Eur Soc Child Adolescent Psychiatry, Paris, France, Sept. 29, 2003.
106. Sclar DA, Skaer TL, Robison WM, Markowitz JS, DeVane CL. Cost of Use Patterns for Atypical Antipsychotics by Race. American Psychiatric Association Institute on Psychiatric Services, Boston, MA, Oct 29-Nov 2, 2003.
107. Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD, Markowitz JS. Effects of cranberry on cytochrome P-450 3A4 and 2D6 activity. 3d International Symposium on Natural Drugs, Naples, Italy, October 9, 2003.

CURRICULUM VITAE

C. LINDSAY DEVANE

108. Donovan JL, Markowitz JS, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Saw Palmetto (*Serenoa repens*) does not significantly alter the activity of cytochrome P-450 3A4 or 2D6. 3d International Symposium on Natural Drugs, Naples, Italy, October 9, 2003.
109. DeVane CL, Wang J-S, Pennick M, Mays DD, McDaniel C, Michaels A, Tulloch S. Effects of amphetamine, methylphenidate, and SPD503 on cytochrome P450 activity. American Academy of Child & Adolescent Psychiatry 50th Annual Meeting, Miami, FL, October 19, 2003.
110. Markowitz JS, Straughn A, Patrick K, DeVane CL, Petreich L, Lee J, Wang Y, Muniz R. Rate and extent of absorption of two methylphenidate formulations. American Academy of Child & Adolescent Psychiatry 50th Annual Meeting, Miami, FL, October 19, 2003.
111. DeVane CL, Wang J-S, Pennick M, Hodgkins P, Mays D, McDaniel , Michaels A, Tulloch S. Effects of amphetamine, methylphenidate, and SPD503 on cytochrome P450 activity. U.S. Psychiatric Mental Health Congress, Orlando, FL, November 9, 2003.
112. DeVane CL, Winter H, Smith MA. Open-label pharmacokinetic study of quetiapine plus divalproex in patients with schizophrenic/schizoaffective disorders or bipolar disorder. 4th International Forum on Mood and Anxiety Disorders. Monte-Carlo, Monaco, November 19, 2003.
113. Donovan JL, Markowitz JS, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Screening herbal preparations for drug interactions by alterations in cytochrome P-450 activity. 1st International Conference on Polyphenols and Health. November 21, 2003 Vichy, France
114. Myrick H, Malcolm R., DeVane CL, Donovan JL, Mojsiak J, Elkashef AM, Taylor R, Brady K. Modafinil is a Potential Treatment for Cocaine Dependence. NCDEU, Phoenix, AZ., June 1, 2004.
115. DeVane CL, Carpenter D, Lipschitz A, Perera P. Immediate vs. Controlled Release Paroxetine : Pharmacokinetic Profile at Steady-state and Impact of CYP2D6 Metabolizer Status. NCDEU, Phoenix, AZ., June 1, 2004.
116. DeVane CL, Winter H, Smith MA. Open-Label Pharmacokinetic Study of Quetiapine plus Divalproex in Patients with Schizophrenic/Schizoaffective disorders or Bipolar Disorder. Fourth European Stanley Conference on Bipolar Disorder, Aarhus, Denmark, September 24, 2004.

CURRICULUM VITAE

C. LINDSAY DEVANE

117. Wang J-S, DeVane CL, Donovan JL, Gison BB, Gefroh HA, Markowitz JS. Cannabinoids Stimulate ATPase Activity of P-glycoprotein. American College of Neuropsychopharmacology Annual Meeting (ACNP), San Juan, P.R., Dec 13, 2004; **Neuropsychopharmacol** 2004;29(Suppl 1):S73.
118. Winn SS, Beach AJ, Henry A, Ritchie J, DeVane CL, Donovan J, Stowe ZN, Newport DJ. Placental passage of atypical antipsychotic medications, North American Society for Psychosocial Obstetrics and Gynecology Annual Meeting, San Diego, February 10-12, 2005.
119. Henry A, Newport DJ, Ritchie JC, DeVane CL, Loughhead A, Stowe ZN. Alterations in SSRI clearance across pregnancy. North American Society for Psychosocial Obstetrics and Gynecology Annual Meeting, San Diego, February 10-12, 2005.